

TEKLA LIFE SCIENCES INVESTORS  
Form N-PX  
August 29, 2016

**UNITED STATES  
SECURITIES AND EXCHANGE  
COMMISSION**

OMB APPROVAL

OMB Number: 3235-0582  
Expires: March 31, 2018  
Estimated average burden hours  
per response.....7.2

Washington, D.C. 20549

**FORM N-PX**

**ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED  
MANAGEMENT INVESTMENT COMPANY**

Investment Company Act file number **811- 06565**

**Tekla Life Sciences Investors**

(Exact name of registrant as specified in charter)

**100 Federal Street, 19th Floor, Boston, MA**  
(Address of principal executive offices)

**02110**  
(Zip code)

**Laura Woodward**  
**Tekla Life Sciences Investors**  
**100 Federal Street, 19th Floor, Boston MA 02110**

(Name and address of agent for service)

Registrant's telephone number, including area code: **617-772-8500**

Date of fiscal year end: **September 30**

## Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Date of reporting period: **7/1/15-6/30/16**

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss. 239.24 and 274.5 of this chapter), to file reports with the Commission, no later than August 31 of each year, containing the registrant's proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (OMB) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

---

**Item 1. Proxy Voting Record.**

---

*Vote Summary***ABAXIS, INC.**

<b>Security</b>	002567105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ABAX	<b>Meeting Date</b>	28-Oct-2015
<b>Record Date</b>	31-Aug-2015		

<b>Item</b>	<b>Proposal</b>	<b>Proposed By</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1 CLINTON H. SEVERSON		For	For
	2 VERNON E. ALTMAN		For	For
	3 RICHARD J BASTIANI, PHD		Withheld	Against
	4 MICHAEL D. CASEY		Withheld	Against
	5 HENK J. EVENHUIS		For	For
	6 PRITHIPAL SINGH, PH.D.		For	For
2.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.	Management	For	For
3.	TO RATIFY THE SELECTION OF BURR PILGER MAYER, INC. AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ABAXIS, INC. FOR THE FISCAL YEAR ENDING MARCH 31, 2016.	Management	For	For

**ACADIA PHARMACEUTICALS INC.**

<b>Security</b>	004225108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ACAD	<b>Meeting Date</b>	10-Jun-2016
<b>Record Date</b>	22-Apr-2016		

<b>Item</b>	<b>Proposal</b>	<b>Proposed By</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1 LAURA BREGE		For	For
	2 STEPHEN DAVIS		For	For
2.	TO APPROVE AN AMENDMENT TO OUR 2004 EMPLOYEE STOCK PURCHASE PLAN TO, AMONG OTHER THINGS, INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE PLAN BY 400,000 SHARES.	Management	For	For
3.	TO APPROVE AN AMENDMENT TO OUR 2010 EQUITY INCENTIVE PLAN, AS AMENDED, TO, AMONG OTHER THINGS, INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE PLAN BY 3,000,000 SHARES.	Management	For	For
4.	TO APPROVE, ON AN ADVISORY BASIS, OUR EXECUTIVE COMPENSATION.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

5.	TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For
----	---	------------	-----	-----

**ACCELERATE DIAGNOSTICS**

<b>Security</b>	00430H102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AXDX	<b>Meeting Date</b>	06-May-2016
<b>Record Date</b>	17-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 LAWRENCE MEHREN		For	For
	2 MARK MILLER		For	For
	3 JOHN PATIENCE		For	For
	4 JACK SCHULER		For	For
	5 MATTHEW STROBECK, PH.D.		For	For
	6 FRANK J.M. TEN BRINK		For	For
2.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS	Management	For	For
3.	TO APPROVE THE ACCELERATE DIAGNOSTICS, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN	Management	For	For
4.	TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT PUBLIC ACCOUNTANTS OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016	Management	For	For

## ADAPTIMMUNE THERAPEUTICS PLC

<b>Security</b>	00653A107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ADAP	<b>Meeting Date</b>	17-Dec-2015
<b>Record Date</b>	13-Nov-2015		

Item	Proposal	Proposed By	Vote	For/Against Management
O1	TO RECEIVE, CONSIDER AND ADOPT THE DIRECTORS AND AUDITOR S REPORTS AND STATEMENT OF ACCOUNTS FOR THE YEAR ENDED 30 JUNE 2015 AND NOTE THAT THE DIRECTORS DO NOT RECOMMEND PAYMENT OF A DIVIDEND.	Management	For	For
O2	TO APPROVE THE DIRECTORS REMUNERATION REPORT.	Management	For	For
O3	TO APPROVE THE DIRECTORS REMUNERATION POLICY WITH EFFECT FROM AFTER THE END OF THE ANNUAL GENERAL MEETING OF THE COMPANY ON 17 DECEMBER 2015.	Management	For	For
O4	TO RE-APPOINT KPMG LLP AS AUDITOR.	Management	For	For
O5	TO AUTHORISE THE DIRECTORS TO DETERMINE THE AUDITOR S REMUNERATION.	Management	For	For
O6	TO AUTHORISE THE DIRECTORS UNDER S551 OF THE COMPANIES ACT 2006 (THE 2006 ACT ) TO ALLOT SHARES OR TO GRANT RIGHTS TO SUBSCRIBE FOR OR TO CONVERT ANY SECURITY INTO SHARES.	Management	For	For
S7	TO AUTHORISE THE DIRECTORS TO ALLOT EQUITY SECURITIES UNDER SECTION 570 OF THE 2006 ACT AS IF SECTION 561(1) OF THE 2006 ACT DID NOT APPLY TO SUCH ALLOTMENT.	Management	For	For

## ADAPTIMMUNE THERAPEUTICS PLC

<b>Security</b>	00653A107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ADAP	<b>Meeting Date</b>	16-Jun-2016
<b>Record Date</b>	03-May-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
O1.	TO RECEIVE, CONSIDER AND ADOPT THE DIRECTORS AND AUDITOR S REPORTS AND STATEMENT OF ACCOUNTS FOR THE PERIOD ENDED 31 DECEMBER 2015 AND NOTE THAT THE DIRECTORS DO NOT RECOMMEND PAYMENT OF A DIVIDEND.	Management	For	
O2.	TO APPROVE THE DIRECTORS REMUNERATION REPORT.	Management	For	
O3.		Management	For	

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

	TO RE-ELECT JAMES NOBLE AS A DIRECTOR OF THE COMPANY.		
O4.	TO RE-ELECT ELLIOTT SIGAL AS A DIRECTOR OF THE COMPANY.	Management	For
O5.	TO RE-APPOINT KPMG LLP AS AUDITOR OF THE COMPANY.	Management	For
O6.	TO AUTHORISE THE AUDIT COMMITTEE TO DETERMINE THE AUDITOR S REMUNERATION.	Management	For
S7.	TO APPROVE THE AMENDMENT OF THE ARTICLES OF ASSOCIATION OF THE COMPANY.	Management	For

AKORN, INC.

<b>Security Ticker Symbol Record Date</b>	009728106 AKRX 11-May-2016	<b>Meeting Type Meeting Date</b>	Annual 01-Jul-2016
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 JOHN KAPOOR, PHD		For	For
	2 KENNETH ABRAMOWITZ		For	For
	3 ADRIENNE GRAVES, PHD		For	For
	4 RONALD JOHNSON		For	For
	5 STEVEN MEYER		For	For
	6 TERRY ALLISON RAPPUHN		For	For
	7 BRIAN TAMBI		For	For
	8 ALAN WEINSTEIN		For	For
2.	PROPOSAL TO RATIFY THE APPOINTMENT OF BDO USA, LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR YEAR ENDING DECEMBER 31, 2016.	Management	For	For
3.	PROPOSAL TO APPROVE, THROUGH A NON-BINDING ADVISORY VOTE, THE COMPANY S EXECUTIVE COMPENSATION PROGRAM AS DESCRIBED IN THE COMPANY S 2016 PROXY STATEMENT.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

**ALEXION PHARMACEUTICALS, INC.**

<b>Security</b>	015351109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALXN	<b>Meeting Date</b>	11-May-2016
<b>Record Date</b>	15-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1A.	ELECTION OF DIRECTOR: LEONARD BELL	Management	For	For
1B.	ELECTION OF DIRECTOR: FELIX BAKER	Management	For	For
1C.	ELECTION OF DIRECTOR: DAVID R. BRENNAN	Management	For	For
1D.	ELECTION OF DIRECTOR: M. MICHELE BURNS	Management	For	For
1E.	ELECTION OF DIRECTOR: CHRISTOPHER J. COUGHLIN	Management	For	For
1F.	ELECTION OF DIRECTOR: DAVID L. HALLAL	Management	For	For
1G.	ELECTION OF DIRECTOR: JOHN T. MOLLEN	Management	For	For
1H.	ELECTION OF DIRECTOR: R. DOUGLAS NORBY	Management	For	For
1I.	ELECTION OF DIRECTOR: ALVIN S. PARVEN	Management	For	For
1J.	ELECTION OF DIRECTOR: ANDREAS RUMMELT	Management	For	For
1K.	ELECTION OF DIRECTOR: ANN M. VENEMAN	Management	For	For
2.	APPROVAL OF A NON-BINDING ADVISORY VOTE OF THE 2015 COMPENSATION PAID TO ALEXION S NAMED EXECUTIVE OFFICERS.	Management	For	For
3.	RATIFICATION OF APPOINTMENT BY BOARD OF PRICEWATERHOUSECOOPERS LLP AS ALEXION S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.	Management	For	For
4.	TO REQUEST THE BOARD TO AMEND ALEXION S GOVERNING DOCUMENTS TO GIVE SHAREHOLDERS OWNING 10% OF ALEXION STOCK THE POWER TO CALL A SPECIAL MEETING.	Shareholder	Against	For

**ALKERMES PLC**

<b>Security</b>	G01767105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALKS	<b>Meeting Date</b>	25-May-2016
<b>Record Date</b>	17-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.1	ELECTION OF DIRECTOR: DAVID W. ANSTICE	Management	For	For
1.2	ELECTION OF DIRECTOR: ROBERT A. BREYER	Management	For	For
1.3	ELECTION OF DIRECTOR: WENDY L. DIXON, PH.D.	Management	For	For
2.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS.	Management	For	For
3.	TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS THE INDEPENDENT AUDITOR OF THE COMPANY AND TO AUTHORIZE THE AUDIT AND RISK	Management	For	For



Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

	COMMITTEE TO SET THE INDEPENDENT AUDITOR S REMUNERATION ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL).			
4.	TO APPROVE THE ALKERMES PLC 2011 STOCK OPTION AND INCENTIVE PLAN, AS AMENDED.	Management	For	For
5.	TO GRANT THE BOARD THE AUTHORITY TO ISSUE SHARES UNDER IRISH LAW.	Management	For	For
6A.	TO APPROVE CERTAIN AMENDMENTS TO THE COMPANY S ARTICLES OF ASSOCIATION THAT ADDRESS THE ADOPTION OF THE IRISH COMPANIES ACT 2014.	Management	For	For
6B.	TO APPROVE CERTAIN AMENDMENTS TO THE COMPANY S MEMORANDUM OF ASSOCIATION THAT ADDRESS THE ADOPTION OF THE IRISH COMPANIES ACT 2014.	Management	For	For
7.	TO GRANT THE BOARD THE AUTHORITY TO OPT-OUT OF STATUTORY PRE-EMPTION RIGHTS UNDER IRISH LAW.	Management	For	For

## ALLERGAN PLC

<b>Security</b>	G0177J108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AGN	<b>Meeting Date</b>	05-May-2016
<b>Record Date</b>	07-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 NESLI BASGOZ, M.D.		For	For
	2 PAUL M. BISARO		For	For
	3 JAMES H. BLOEM		For	For
	4 CHRISTOPHER W. BODINE		For	For
	5 CHRISTOPHER J. COUGHLIN		For	For
	6 MICHAEL R. GALLAGHER		For	For
	7 CATHERINE M. KLEMA		For	For
	8 PETER J. MCDONNELL, M.D		For	For
	9 PATRICK J. O SULLIVAN		For	For
	10 BRENTON L. SAUNDERS		For	For
	11 RONALD R. TAYLOR		For	For
	12 FRED G. WEISS		For	For
2.	TO APPROVE, IN A NON-BINDING VOTE, NAMED EXECUTIVE OFFICER COMPENSATION	Management	For	For
3.	TO RATIFY, IN A NON-BINDING VOTE, THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS THE COMPANY S INDEPENDENT AUDITOR FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016 AND TO AUTHORIZE, IN A BINDING VOTE, THE BOARD OF DIRECTORS, ACTING THROUGH THE AUDIT AND COMPLIANCE COMMITTEE, TO DETERMINE PRICEWATERHOUSECOOPERS LLP S REMUNERATION	Management	For	For
4A.	TO APPROVE THE AMENDMENT OF THE COMPANY S: MEMORANDUM OF ASSOCIATION TO MAKE CERTAIN ADMINISTRATIVE AMENDMENTS	Management	For	For
4B.	TO APPROVE THE AMENDMENT OF THE COMPANY S: ARTICLES OF ASSOCIATION TO MAKE CERTAIN ADMINISTRATIVE AMENDMENTS	Management	For	For
5A.	TO APPROVE THE AMENDMENT OF THE COMPANY S ARTICLES OF ASSOCIATION IN ORDER TO: PROVIDE FOR A PLURALITY VOTING STANDARD IN THE EVENT OF A CONTESTED ELECTION	Management	For	For
5B.	TO APPROVE THE AMENDMENT OF THE COMPANY S ARTICLES OF ASSOCIATION IN ORDER TO: GRANT THE BOARD OF DIRECTORS SOLE AUTHORITY TO DETERMINE ITS SIZE	Management	For	For
6.	TO APPROVE THE REDUCTION OF COMPANY CAPITAL	Management	For	For
7.	TO CONSIDER A SHAREHOLDER PROPOSAL REGARDING AN ANNUAL REPORT ON LOBBYING ACTIVITIES, IF PROPERLY PRESENTED AT THE MEETING	Shareholder	Against	For
8.	TO CONSIDER A SHAREHOLDER PROPOSAL REGARDING AN INDEPENDENT BOARD CHAIRMAN, IF PROPERLY PRESENTED AT THE MEETING	Shareholder	Against	For

## ALLIQUA BIOMEDICAL, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	019621200	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALQA	<b>Meeting Date</b>	06-May-2016
<b>Record Date</b>	11-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 DAVID JOHNSON		For	For
	2 WINSTON KUNG		For	For
	3 JOSEPH LEONE		For	For
	4 GARY RESTANI		For	For
	5 JEFFREY SKLAR		For	For
	6 MARK WAGNER		For	For
	7 JEROME ZELDIS, MD, PHD.		For	For
2.	APPROVAL OF AN AMENDMENT TO OUR CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 45,714,286 TO 95,000,000.	Management	For	For
3.	RATIFICATION OF THE APPOINTMENT OF MARCUM LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

ALNYLAM PHARMACEUTICALS, INC.

<b>Security</b>	02043Q107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ALNY	<b>Meeting Date</b>	03-May-2016
<b>Record Date</b>	11-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.1	ELECTION OF CLASS III DIRECTOR: STEVEN M. PAUL, M.D.	Management	For	For
1.2	ELECTION OF CLASS III DIRECTOR: AMY W. SCHULMAN	Management	For	For
1.3	ELECTION OF CLASS III DIRECTOR: KEVIN P. STARR	Management	For	For
2.	TO APPROVE, IN A NON-BINDING ADVISORY VOTE, THE COMPENSATION OF ALNYLAM S NAMED EXECUTIVE OFFICERS.	Management	For	For
3.	TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP, AN INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM, AS ALNYLAM S INDEPENDENT AUDITORS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

## ALTERG, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	1-Feb-2016
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	WAIVER OF REQUIREMENT FOR AUDITED FINANCIAL STATEMENTS	Management	For	For
2	ADDITIONAL PROVISIONS	Management	For	For

## AMGEN INC.

<b>Security</b>	031162100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	AMGN	<b>Meeting Date</b>	19-May-2016
<b>Record Date</b>	21-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1A.	ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: DR. DAVID BALTIMORE	Management	For	For
1B.	ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MR. FRANK J. BIONDI, JR.	Management	For	For
1C.	ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MR. ROBERT A. BRADWAY	Management	For	For
1D.	ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MR. FRANCOIS DE CARBONNEL	Management	For	For
1E.	ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MR. ROBERT A. ECKERT	Management	For	For
1F.	ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MR. GREG C. GARLAND	Management	For	For
1G.	ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MR. FRED HASSAN	Management	For	For
1H.	ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: DR. REBECCA M. HENDERSON	Management	For	For
1I.	ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MR. FRANK C. HERRINGER	Management	For	For
1J.	ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: DR. TYLER JACKS	Management	For	For
1K.	ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: MS. JUDITH C. PELHAM	Management	For	For
1L.	ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: DR. RONALD D. SUGAR	Management	For	For
1M.	ELECTION OF DIRECTOR FOR A TERM EXPIRING AT 2017: DR. R. SANDERS WILLIAMS	Management	For	For
2.	TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

3.	ADVISORY VOTE TO APPROVE OUR EXECUTIVE COMPENSATION.	Management	For	For
4.	STOCKHOLDER PROPOSAL TO CHANGE THE VOTING STANDARD APPLICABLE TO NON-BINDING PROPOSALS SUBMITTED BY STOCKHOLDERS.	Shareholder	Against	For

AMICUS THERAPEUTICS, INC.

<b>Security</b>	03152W109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	FOLD	<b>Meeting Date</b>	09-Jun-2016
<b>Record Date</b>	15-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 JOHN F. CROWLEY		For	For
	2 MARGARET G. MCGLYNN RPH		For	For
	3 MICHAEL G. RAAB		For	For
	4 GLENN P. SBLENDORIO		For	For
2.	APPROVE THE AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN.	Management	For	For
3.	APPROVE THE ISSUANCE OF SHARES OF THE COMPANY S COMMON STOCK IN CONNECTION WITH A SPECIFIC MILESTONE PAYMENT THAT MAY BECOME PAYABLE TO THE FORMER SCIODERM STOCKHOLDERS, IN ACCORDANCE WITH THE MARKETPLACE RULES OF THE NASDAQ STOCK MARKET, LLC.	Management	For	For
4.	RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For
5.	APPROVE, ON AN ADVISORY BASIS, THE COMPANY S EXECUTIVE COMPENSATION.	Management	For	For

## ANACOR PHARMACEUTICALS INC

<b>Security</b>	032420101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ANAC	<b>Meeting Date</b>	07-Jun-2016
<b>Record Date</b>	12-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 PAUL L. BERNS		For	For
	2 LUCY SHAPIRO, PH.D.		For	For
	3 WENDELL WIERENGA, PH.D.		For	For
2.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE YEAR ENDING DECEMBER 31, 2016.	Management	For	For
3.	TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.	Management	For	For
4.	TO RE-APPROVE THE SECTION 162(M) PERFORMANCE GOALS UNDER THE COMPANY'S 2010 EQUITY INCENTIVE PLAN.	Management	For	For

## ARDELYX, INC

<b>Security</b>	039697107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ARDX	<b>Meeting Date</b>	02-Jun-2016
<b>Record Date</b>	08-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 DAVID MOTT		For	For
	2 MICHAEL RAAB		For	For
2.	TO RATIFY THE SELECTION, BY THE AUDIT COMMITTEE OF OUR BOARD OF DIRECTORS, OF ERNST & YOUNG, LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016.	Management	For	For

## ARIAD PHARMACEUTICALS, INC.

<b>Security</b>	04033A100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ARIA	<b>Meeting Date</b>	21-Jul-2016
<b>Record Date</b>	25-May-2016		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed By	Vote	For/Against Management
1.	TO ADOPT AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION TO DECLASSIFY THE BOARD OF DIRECTORS AND PROVIDE FOR THE ANNUAL ELECTION OF DIRECTORS.	Management	For	For
2A.	TO ELECT CLASS 1 DIRECTOR TO SERVE ON OUR BOARD OF DIRECTORS: ALEXANDER J. DENNER, PH.D.	Management	For	For
3.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT.	Management	For	For
4.	TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR 2016.	Management	For	For

## AURIS MEDICAL HOLDING AG

<b>Security</b>	H03579101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	EARS	<b>Meeting Date</b>	08-Apr-2016
<b>Record Date</b>	10-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
G1	GENERAL INSTRUCTIONS ON THE PROPOSALS OF THE BOARD OF DIRECTORS	Management	For	For
G2	GENERAL INSTRUCTIONS ON NEW PROPOSALS OF THE BOARD OF DIRECTORS/ NEW AGENDA ITEMS	Management	For	For
S1	APPROVAL OF THE ANNUAL REPORT, THE FINANCIAL STATEMENTS AND THE GROUP CONSOLIDATED FINANCIAL STATEMENTS FOR THE 2015 FINANCIAL YEAR	Management	For	For
S2	DISCHARGE OF THE MEMBERS OF THE BOARD AND THE PERSONS ENTRUSTED WITH THE COMPANY S MANAGEMENT	Management	For	For
S3	APPROPRIATION OF FINANCIAL RESULTS	Management	For	For
S4A	INCREASE AND AMENDMENT OF THE AUTHORIZED SHARE CAPITAL	Management	For	For
S4B	INCREASE AND AMENDMENT OF THE CONDITIONAL SHARE CAPITAL	Management	For	For
S4C	CANCELLATION OF ARTICLE 5 OF THE ARTICLES OF ASSOCIATION	Management	For	For
S5A	APPROVAL OF THE COMPENSATION OF THE BOARD OF DIRECTORS	Management	For	For
S5B	APPROVAL OF THE COMPENSATION OF THE MEMBERS OF THE EXECUTIVE MANAGEMENT COMMITTEE FOR THE 2015 FINANCIAL YEAR	Management	For	For
S5C	APPROVAL OF THE COMPENSATION OF THE MEMBERS OF THE EXECUTIVE MANAGEMENT COMMITTEE FOR THE 2017 FINANCIAL YEAR	Management	For	For
S6A	RE-ELECTION OF THOMAS MEYER AS MEMBER AND CHAIRMAN	Management	For	For
S6B	RE-ELECTION OF JAMES I. HEALY AS MEMBER OF THE BOARD	Management	For	For
S6C	RE-ELECTION OF WOLFGANG ARNOLD AS MEMBER OF THE BOARD	Management	For	For
S6D	RE-ELECTION OF OLIVER KUBLI AS MEMBER OF THE BOARD	Management	For	For
S6E	RE-ELECTION OF BERNDT A. MODIG AS MEMBER OF THE BOARD	Management	For	For
S6F	RE-ELECTION OF ANTOINE PAPIERNIK AS MEMBER OF THE BOARD	Management	For	For
S6G	RE-ELECTION OF CALVIN W. ROBERTS AS MEMBER OF THE BOARD	Management	For	For
S6H	ELECTION OF ARMANDO ANIDO AS MEMBER OF THE BOARD	Management	For	For
S7A	RE-ELECTION OF JAMES I. HEALY AS MEMBER OF THE COMPENSATION COMMITTEE	Management	For	For
S7B	RE-ELECTION OF ANTOINE PAPIERNIK AS MEMBER OF THE COMPENSATION COMMITTEE	Management	For	For
S7C		Management	For	For



Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

ELECTION OF ARMANDO ANIDO AS MEMBER OF  
THE COMPENSATION COMMITTEE

S8	RE-ELECTION OF DELOITTE AG AS AUDITORS	Management	For	For
S9	RE-ELECTION OF THE INDEPENDENT PROXY SANDRO G. TOBLER	Management	For	For

**BELLICUM PHARMACEUTICALS INC**

<b>Security</b>	079481107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BLCM	<b>Meeting Date</b>	15-Jun-2016
<b>Record Date</b>	18-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 JAMES F. BROWN		For	For
	2 KEVIN M. SLAWIN, M.D.		For	For
2.	RATIFICATION OF SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

**BIODELIVERY SCIENCES INTERNATIONAL, INC.**

<b>Security</b>	09060J106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BDSI	<b>Meeting Date</b>	16-Jul-2015
<b>Record Date</b>	05-Jun-2015		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 FRANCIS E. O DONNELL JR		For	For
	2 SAMUEL P. SEARS, JR.		For	For
	3 BARRY I. FEINBERG		For	For
2.	TO RATIFY THE APPOINTMENT BY THE AUDIT COMMITTEE OF THE COMPANY S BOARD OF DIRECTORS OF CHERRY BEKAERT LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2015.	Management	For	For
3.	TO APPROVE AN AMENDMENT TO THE 2011 EQUITY INCENTIVE PLAN TO, AMONG OTHER MATTERS, INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE 2011 PLAN FROM 8,800,000 TO 11,050,000.	Management	For	For
4.	IN THEIR DISCRETION, UPON THE TRANSACTION OF ANY OTHER MATTERS WHICH MAY PROPERLY COME BEFORE THE MEETING OR ANY ADJOURNMENT THEREOF.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

**BIOGEN INC.**

<b>Security</b>	09062X103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BIIB	<b>Meeting Date</b>	08-Jun-2016
<b>Record Date</b>	11-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1A.	ELECTION OF DIRECTOR: ALEXANDER J. DENNER	Management	For	For
1B.	ELECTION OF DIRECTOR: CAROLINE D. DORSA	Management	For	For
1C.	ELECTION OF DIRECTOR: NANCY L. LEAMING	Management	For	For
1D.	ELECTION OF DIRECTOR: RICHARD C. MULLIGAN	Management	For	For
1E.	ELECTION OF DIRECTOR: ROBERT W. PANGIA	Management	For	For
1F.	ELECTION OF DIRECTOR: STELIOS PAPADOPOULOS	Management	For	For
1G.	ELECTION OF DIRECTOR: BRIAN S. POSNER	Management	For	For
1H.	ELECTION OF DIRECTOR: ERIC K. ROWINSKY	Management	For	For
1I.	ELECTION OF DIRECTOR: GEORGE A. SCANGOS	Management	For	For
1J.	ELECTION OF DIRECTOR: LYNN SCHENK	Management	For	For
1K.	ELECTION OF DIRECTOR: STEPHEN A. SHERWIN	Management	For	For
2.	TO RATIFY THE SELECTION OF PRICEWATERHOUSECOOPERS LLP AS BIOGEN INC. S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For
3.	SAY ON PAY - TO APPROVE AN ADVISORY VOTE ON EXECUTIVE COMPENSATION.	Management	For	For

**BIOMARIN PHARMACEUTICAL INC.**

<b>Security</b>	09061G101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BMRN	<b>Meeting Date</b>	06-Jun-2016
<b>Record Date</b>	11-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 JEAN-JACQUES BIENAIME		For	For
	2 MICHAEL GREY		For	For
	3 ELAINE J. HERON		For	For
	4 V. BRYAN LAWLIS		For	For
	5 ALAN J. LEWIS		For	For
	6 RICHARD A. MEIER		For	For
	7 DAVID PYOTT		For	For
	8 DENNIS J. SLAMON		For	For
2.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF BIOMARIN S NAMED EXECUTIVE OFFICERS AS DEFINED AND DISCLOSED IN ITS PROXY STATEMENT.	Management	For	For
3.		Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

TO RATIFY THE SELECTION OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR BIOMARIN FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.

4.	A STOCKHOLDER PROPOSAL REQUESTING THAT BIOMARIN ISSUE A SUSTAINABILITY REPORT DESCRIBING BIOMARIN'S ENVIRONMENTAL, SOCIAL AND GOVERNANCE PERFORMANCE, IF PROPERLY PRESENTED AT BIOMARIN'S ANNUAL MEETING OF STOCKHOLDERS.	Shareholder	Against	For
----	---	-------------	---------	-----

**BLUEBIRD BIO INC.**

<b>Security</b>	09609G100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	BLUE	<b>Meeting Date</b>	02-Jun-2016
<b>Record Date</b>	08-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 WENDY DIXON		For	For
	2 JAMES MANDELL		For	For
	3 DAVID SCHENKEIN		For	For
2.	ADVISORY VOTE ON EXECUTIVE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS.	Management	For	For
3.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

## CARDIOKINETIX, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	11-Apr-2016
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	ELECTION OF DANIEL OMSTEAD TO THE BOARD OF DIRECTORS	Management	For	For
2	OMNIBUS RESOLUTIONS	Management	For	For

## CELATOR PHARMACEUTICALS, INC.

<b>Security</b>	15089R102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CPXX	<b>Meeting Date</b>	06-Jun-2016
<b>Record Date</b>	22-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 MICHAEL R. DOUGHERTY		For	For
	2 SCOTT T. JACKSON		For	For
	3 JEAN-PIERRE BIZZARI		For	For
	4 RICHARD S. KOLLENDER		For	For
	5 JOSEPH M. LOBACKI		For	For
	6 JOSEPH A. MOLLIKA		For	For
	7 SCOTT MORENSTEIN		For	For
	8 NICOLE VITULLO		For	For
2.	THE RATIFICATION OF KPMG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

## CELGENE CORPORATION

<b>Security</b>	151020104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CELG	<b>Meeting Date</b>	15-Jun-2016
<b>Record Date</b>	18-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 ROBERT J. HUGIN		For	For
	2 MARK J. ALLES		For	For
	3 RICHARD W BARKER D PHIL		For	For
	4 MICHAEL W. BONNEY		For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

	5	MICHAEL D. CASEY		For	For
	6	CARRIE S. COX		For	For
	7	JACQUALYN A. FOUSE, PHD		For	For
	8	MICHAEL A. FRIEDMAN, MD		For	For
	9	JULIA A. HALLER, M.D.		For	For
	10	GILLA S. KAPLAN, PH.D.		For	For
	11	JAMES J. LOUGHLIN		For	For
	12	ERNEST MARIO, PH.D.		For	For
2.		RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For
3.		APPROVAL OF AN AMENDMENT TO THE COMPANY S 2008 STOCK INCENTIVE PLAN.	Management	For	For
4.		APPROVAL, BY NON-BINDING VOTE, OF EXECUTIVE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS.	Management	For	For
5.		RATIFICATION OF AN AMENDMENT TO THE COMPANY S BY-LAWS.	Management	For	For
6.		STOCKHOLDER PROPOSAL TO REQUEST A BY-LAW PROVISION GRANTING STOCKHOLDERS THE RIGHT TO CALL SPECIAL MEETINGS, DESCRIBED IN MORE DETAIL IN THE PROXY STATEMENT.	Shareholder	Against	For
7.		STOCKHOLDER PROPOSAL TO REQUEST A PROXY ACCESS BY-LAW PROVISION, DESCRIBED IN MORE DETAIL IN THE PROXY STATEMENT.	Shareholder	Against	For

CELLECTIS S.A.

<b>Security</b>	15117K103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CLLS	<b>Meeting Date</b>	17-May-2016
<b>Record Date</b>	18-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	APPROVAL OF THE ANNUAL FINANCIAL STATEMENTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015	Management	For	For
2.	APPROVAL OF THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015	Management	For	For
3.	ALLOCATION OF INCOME FOR THE FISCAL YEAR ENDED DECEMBER 31, 2015	Management	For	For
4.	APPROVAL OF THE AGREEMENTS REFERRED TO IN ARTICLES L. 225-38 AND FOLLOWING OF THE FRENCH COMMERCIAL CODE	Management	For	For
5.	REAPPOINTMENT OF MR. MATHIEU SIMON TO THE BOARD OF DIRECTORS	Management	For	For
6.	AUTHORIZATION TO BE GIVEN TO THE BOARD OF DIRECTORS TO BUY BACK COMPANY SHARES	Management	For	For
7.	AUTHORIZATION TO BE GIVEN TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF REDUCING THE SHARE CAPITAL THROUGH THE CANCELLATION OF SHARES IN THE CONTEXT OF THE AUTHORIZATION TO BUY BACK ITS OWN SHARES	Management	For	For
8.	DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

	INCREASING THE SHARE CAPITAL BY ISSUING ORDINARY SHARES AND/OR ANY SECURITIES GIVING ACCESS IMMEDIATELY OR IN THE FUTURE TO THE SHARE CAPITAL AND/OR GIVING ENTITLEMENT TO THE ALLOTMENT OF DEBT SECURITIES, WITH A WAIVER OF THE PREFERENTIAL SUBSCRIPTION RIGHTS, IN FAVOR OF A CATEGORY OF PERSONS MEETING SPECIFIED CHARACTERISTICS			
9.	DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL THROUGH THE ISSUANCE OF ORDINARY SHARES OR OF ANY SECURITIES WITH A WAIVER OF THE PREFERENTIAL SUBSCRIPTION RIGHTS, IN FAVOR OF A CATEGORY OF PERSONS ENSURING THE UNDERWRITING OF THE COMPANY'S EQUITY SECURITIES THAT MAY ARISE AS PART OF A LINE OF EQUITY FINANCING	Management	For	For
10.	DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL IMMEDIATELY OR IN THE FUTURE BY ISSUING ORDINARY SHARES OR ANY SECURITIES GIVING ACCESS IMMEDIATELY OR IN THE FUTURE TO THE SHARE CAPITAL OR GIVING ENTITLEMENT TO THE ALLOTMENT OF DEBT SECURITIES, WHILE MAINTAINING THE PREFERENTIAL SUBSCRIPTION RIGHTS	Management	For	For
11.	DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL IMMEDIATELY OR IN THE FUTURE THROUGH THE ISSUANCE OF ORDINARY SHARES OR OF ANY SECURITIES GIVING ACCESS IMMEDIATELY OR IN THE FUTURE TO THE SHARE CAPITAL OR GIVING ENTITLEMENT TO THE ALLOTMENT OF DEBT SECURITIES, WITH A WAIVER OF THE PREFERENTIAL SUBSCRIPTION RIGHTS AND PUBLIC OFFERING	Management	For	For
12.	DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL THROUGH THE ISSUANCE OF ORDINARY SHARES AND/OR OF ANY SECURITIES GIVING ACCESS IMMEDIATELY OR IN THE FUTURE TO THE SHARE CAPITAL OR GIVING ENTITLEMENT TO THE ALLOTMENT OF DEBT SECURITIES, WITH A WAIVER OF THE PREFERENTIAL SUBSCRIPTION RIGHTS OF THE SHAREHOLDERS, THROUGH AN OFFER TO QUALIFIED INVESTORS OR A LIMITED CIRCLE OF INVESTORS WITHIN THE MEANING OF PARAGRAPH II OF ARTICLE L. 411-2 OF THE FRENCH MONETARY AND FINANCIAL CODE	Management	For	For
13.	DELEGATION GRANTED TO THE BOARD OF DIRECTORS TO INCREASE THE NUMBER OF SECURITIES TO BE ISSUED IN CASE OF SHARE CAPITAL INCREASE WITH OR WITHOUT PREFERENTIAL SUBSCRIPTION RIGHTS	Management	For	For
14.	OVERALL LIMITATIONS TO THE AMOUNT OF ISSUANCES MADE UNDER THE EIGHTH RESOLUTION, THE NINTH RESOLUTION, THE	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

TENTH RESOLUTION, THE ELEVENTH RESOLUTION, THE TWELFTH RESOLUTION AND THE THIRTEENTH RESOLUTION ABOVE

15.	DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF INCREASING THE SHARE CAPITAL BY INCORPORATION OF PREMIUMS, RESERVES, PROFITS OR OTHERS	Management	For	For
16.	AUTHORIZATION TO BE GIVEN TO THE BOARD OF DIRECTORS TO GRANT OPTIONS TO SUBSCRIBE OR PURCHASE COMPANY S SHARES	Management	For	For
17.	AUTHORIZATION TO BE GIVEN TO THE BOARD OF DIRECTORS FOR THE ALLOCATION OF FREE SHARES EXISTING AND/OR TO BE ISSUED IN THE FUTURE	Management	For	For
18.	DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS TO ISSUE AND GRANT SHARE WARRANTS TO (I) MEMBERS AND NON-VOTING MEMBERS (CENSEURS) OF THE COMPANY S BOARD OF DIRECTORS IN OFFICE ON THE DATE THE WARRANTS ARE GRANTED WHO ARE NOT EMPLOYEES OR SENIOR EXECUTIVES OF THE COMPANY OR ONE OF ITS SUBSIDIARIES OR (II) PERSONS WHO HAVE ENTERED INTO A SERVICES OR CONSULTANTS CONTRACT WITH THE COMPANY OR WITH ONE OF ITS SUBSIDIARIES OR (III) MEMBERS OF ANY COMMITTEE WHICH THE BOARD OF DIRECTORS ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL)	Management	For	For
19.	DELEGATION OF AUTHORITY TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF ISSUING WARRANTS TO SUBSCRIBE TO AND/OR ACQUIRE REDEEMABLE SHARES (BSAAR) OR SHARE SUBSCRIPTION WARRANTS - WITH A WAIVER OF THE PREFERENTIAL SUBSCRIPTION RIGHTS IN FAVOR OF THE FOLLOWING CATEGORY OF BENEFICIARIES: EMPLOYEES AND CORPORATE OFFICERS OF THE COMPANY AND ITS SUBSIDIARIES	Management	For	For
20.	AUTHORIZATION FOR THE BOARD OF DIRECTORS TO FREELY ALLOCATE PREFERRED SHARES OF THE COMPANY TO THE EMPLOYEES AND/OR THE EXECUTIVE OFFICERS OF THE COMPANY AND ITS SUBSIDIARIES ENTAILING THE WAIVER BY THE SHAREHOLDERS OF THEIR PREFERENTIAL SUBSCRIPTION RIGHTS	Management	For	For
21.	OVERALL LIMITATIONS TO THE AMOUNT OF ISSUES MADE UNDER THE SIXTEENTH RESOLUTION, THE SEVENTEENTH RESOLUTION, THE EIGHTEENTH RESOLUTION, THE NINETEENTH RESOLUTION AND THE TWENTIETH RESOLUTION ABOVE	Management	For	For
22.	DELEGATION TO BE GRANTED TO THE BOARD OF DIRECTORS FOR THE PURPOSE OF AN INCREASE IN THE SHARE CAPITAL WHOSE SUBSCRIPTION WOULD BE RESERVED TO MEMBERS OF A COMPANY SAVINGS PLAN ESTABLISHED PURSUANT TO ARTICLES L. 3332-18 AND FOLLOWING OF THE FRENCH LABOR CODE	Shareholder	Against	For

## CEPHEID

<b>Security</b>	15670R107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CPHD	<b>Meeting Date</b>	26-Apr-2016
<b>Record Date</b>	04-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1A.	TO ELECT CLASS II DIRECTOR TO SERVE FOR A THREE-YEAR TERM: THOMAS L. GUTSHALL	Management	For	For
1B.	TO ELECT CLASS II DIRECTOR TO SERVE FOR A THREE-YEAR TERM: CRISTINA H. KEPNER	Management	For	For
1C.	TO ELECT CLASS II DIRECTOR TO SERVE FOR A THREE-YEAR TERM: DAVID H. PERSING, M.D., PH.D.	Management	For	For
2.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF CEPHEID FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For
3.	TO APPROVE A NON-BINDING ADVISORY RESOLUTION ON CEPHEID S EXECUTIVE COMPENSATION.	Management	For	For

## CHIMERIX INC.

<b>Security</b>	16934W106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CMRX	<b>Meeting Date</b>	24-Jun-2016
<b>Record Date</b>	27-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 C L GILLISS PHD RN FAAN		For	For
	2 C. PATRICK MACHADO		For	For
	3 ERNEST MARIO, PH.D.		For	For
2.	RATIFICATION OF THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For
3.	TO APPROVE, BY NON-BINDING VOTE, THE COMPENSATION OF CHIMERIX, INC. S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT.	Management	Against	Against
4.	TO RECOMMEND, BY NON-BINDING VOTE, THE FREQUENCY OF EXECUTIVE COMPENSATION VOTES.	Management	1 Year	For



## CIDARA THERAPEUTICS, INC.

<b>Security</b>	171757107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CDTX	<b>Meeting Date</b>	22-Jun-2016
<b>Record Date</b>	25-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 SCOTT ROCKLAGE, PH.D.		For	For
	2 JEFFREY STEIN, PH.D.		For	For
2.	RATIFICATION OF THE APPOINTMENT OF THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2016	Management	For	For

## CYTOMX THERAPEUTICS, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	01-Oct-2015
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	APPROVAL OF REVERSE STOCK SPLIT; AUTHORIZATION OF AMENDMENT AND RESTATEMENT OF CERTIFICATE OF INCORPORATION	Management	For	For
2	WRITTEN CONSENT: COUNTERPARTS	Management	For	For

## CYTOMX THERAPEUTICS, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	06-Oct-2015
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	APPROVAL OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION	Management	For	For
2	ADOPTION OF AMENDED AND RESTATED BYLAWS	Management	For	For
3	FURTHER GRANT OF AUTHORITY	Management	For	For

## CYTOMX THERAPEUTICS, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	23284F105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	CTMX	<b>Meeting Date</b>	10-Jun-2016
<b>Record Date</b>	12-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1A.	ELECTION OF DIRECTOR: SEAN A. MCCARTHY	Management	For	For
2.	TO RATIFY THE SELECTION OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For
3.	TO ADOPT AND APPROVE THE CYTOMX THERAPEUTICS, INC. ANNUAL INCENTIVE PLAN.	Management	For	For
4.	TO APPROVE THE PERFORMANCE MEASURES INCLUDED IN THE CYTOMX THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN.	Management	For	For

**DEPOMED, INC.**

<b>Security</b>	249908104	<b>Meeting Type</b>	Contested-Consent
<b>Ticker Symbol</b>	DEPO	<b>Meeting Date</b>	20-Nov-2015
<b>Record Date</b>	29-Oct-2015		

Item	Proposal	Proposed By	Vote	For/Against Management
01	THIS PROPOSAL REFERS TO THE WHITE CARD. THIS VIF, WHEN PROPERLY EXECUTED, WILL GRANT HORIZON A PROXY TO REQUEST THE REMOVAL AND BYLAW AMENDMENTS SPECIAL MEETING BUT WILL NOT GRANT HORIZON AUTHORITY TO VOTE ON ANY MATTER PRESENTED AT THE REMOVAL AND BYLAW AMENDMENTS SPECIAL MEETING. A PROPERLY EXECUTED VIF FOR WHICH NO INSTRUCTION IS GIVEN WILL GRANT HORIZON A PROXY TO REQUEST THE REMOVAL AND BYLAW AMENDMENTS SPECIAL MEETING.	Management	Against	Against
02	THIS PROPOSAL REFERS TO THE BLUE CARD. THIS VIF, WHEN PROPERLY EXECUTED, WILL GRANT HORIZON A PROXY TO REQUEST THE ELECTION SPECIAL MEETING BUT WILL NOT GRANT HORIZON AUTHORITY TO VOTE ON ANY MATTER PRESENTED AT THE ELECTION SPECIAL MEETING. A PROPERLY EXECUTED VIF FOR WHICH NO INSTRUCTION IS GIVEN WILL GRANT HORIZON A PROXY TO REQUEST THE ELECTION SPECIAL MEETING.	Management	Against	Against

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

DEPOMED, INC.

<b>Security</b>	249908104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	DEPO	<b>Meeting Date</b>	18-May-2016
<b>Record Date</b>	31-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.1	ELECTION OF DIRECTOR: PETER D. STAPLE	Management	For	For
1.2	ELECTION OF DIRECTOR: KAREN A. DAWES	Management	For	For
1.3	ELECTION OF DIRECTOR: LOUIS J. LAVIGNE, JR.	Management	For	For
1.4	ELECTION OF DIRECTOR: SAMUEL R. SAKS, M.D.	Management	For	For
1.5	ELECTION OF DIRECTOR: JAMES A. SCHOENECK	Management	For	For
1.6	ELECTION OF DIRECTOR: DAVID B. ZENOFF, D.B.A.	Management	For	For
2.	TO APPROVE AN INCREASE IN THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE UNDER THE COMPANY S AMENDED AND RESTATED 2014 OMNIBUS INCENTIVE PLAN.	Management	For	For
3.	TO APPROVE AN INCREASE IN THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE UNDER THE COMPANY S AMENDED AND RESTATED 2004 EMPLOYEE STOCK PURCHASE PLAN.	Management	For	For
4.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS.	Management	For	For
5.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

DYNAVAX TECHNOLOGIES CORPORATION

<b>Security</b>	268158201	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	DVAX	<b>Meeting Date</b>	31-May-2016
<b>Record Date</b>	06-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 DENNIS A. CARSON, M.D.		For	For
	2 EDDIE GRAY		For	For
	3 LAURA BREGE		For	For
2.	TO AMEND AND RESTATE THE DYNAVAX TECHNOLOGIES CORPORATION 2011 EQUITY INCENTIVE PLAN TO, AMONG OTHER THINGS, INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THAT PLAN BY 3,200,000, AND TO APPROVE THE AWARD LIMITS AND OTHER TERMS APPLICABLE TO AWARDS INTENDED TO QUALIFY AS PERFORMANCE-BASED COMPENSATION	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

FOR PURPOSES OF SECTION 162(M) OF THE INTERNAL REVENUE CODE.

3.	TO AMEND AND RESTATE THE DYNAVAX TECHNOLOGIES CORPORATION 2014 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THAT PLAN BY 200,000.	Management	For	For
4.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.	Management	For	For
5.	TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

ENDO INTERNATIONAL PLC

<b>Security Ticker Symbol Record Date</b>	G30401106 ENDP 14-Apr-2016	<b>Meeting Type Meeting Date</b>	Annual 09-Jun-2016
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed By	Vote	For/Against Management
1A.	ELECTION OF DIRECTOR: ROGER H. KIMMEL	Management	For	For
1B.	ELECTION OF DIRECTOR: RAJIV DE SILVA	Management	For	For
1C.	ELECTION OF DIRECTOR: SHANE M. COOKE	Management	For	For
1D.	ELECTION OF DIRECTOR: ARTHUR J. HIGGINS	Management	For	For
1E.	ELECTION OF DIRECTOR: NANCY J. HUTSON, PH.D.	Management	For	For
1F.	ELECTION OF DIRECTOR: MICHAEL HYATT	Management	For	For
1G.	ELECTION OF DIRECTOR: WILLIAM P. MONTAGUE	Management	For	For
1H.	ELECTION OF DIRECTOR: JILL D. SMITH	Management	For	For
1I.	ELECTION OF DIRECTOR: WILLIAM F. SPENGLER	Management	For	For
2.	TO APPROVE THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS THE COMPANY'S INDEPENDENT AUDITORS FOR THE YEAR ENDING DECEMBER 31, 2016 AND TO AUTHORIZE THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS TO DETERMINE THE AUDITORS' REMUNERATION.	Management	For	For
3.	TO APPROVE, BY ADVISORY VOTE, NAMED EXECUTIVE OFFICER COMPENSATION.	Management	For	For
4.	TO APPROVE THE AMENDMENT OF THE COMPANY'S MEMORANDUM OF ASSOCIATION.	Management	For	For
5.	TO APPROVE THE AMENDMENT OF THE COMPANY'S ARTICLES OF ASSOCIATION.	Management	For	For
6.	TO APPROVE THE AMENDMENT OF THE COMPANY'S 2015 STOCK INCENTIVE PLAN.	Management	For	For
1J.	ELECTION OF DIRECTOR: DOUGLAS S. INGRAM	Management	For	For
1K.	ELECTION OF DIRECTOR: TODD SISITSKY	Management	For	For

## EPIZYME INC.

<b>Security</b>	29428V104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	EPZM	<b>Meeting Date</b>	19-May-2016
<b>Record Date</b>	01-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 DAVID M. MOTT		For	For
	2 RICHARD F. POFS		For	For
2.	RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS EPIZYME S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

## EXELIXIS, INC.

<b>Security</b>	30161Q104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	EXEL	<b>Meeting Date</b>	25-May-2016
<b>Record Date</b>	31-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.1	ELECTION OF CLASS II DIRECTOR: CARL B. FELDBAUM, ESQ.	Management	For	For
1.2	ELECTION OF CLASS II DIRECTOR: ALAN M. GARBER, M.D., PH.D.	Management	For	For
1.3	ELECTION OF CLASS II DIRECTOR: VINCENT T. MARCHESI, M.D., PH.D.	Management	For	For
2.	TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS EXELIXIS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 30, 2016.	Management	For	For
3.	TO APPROVE AN AMENDMENT AND RESTATEMENT OF THE EXELIXIS, INC. 2000 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE UNDER THE 2000 EMPLOYEE STOCK PURCHASE PLAN BY 5,000,000 SHARES AND MAKE CERTAIN OTHER CHANGES AS DESCRIBED IN PROPOSAL 3 OF THE ACCOMPANYING PROXY STATEMENT.	Management	For	For
4.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF EXELIXIS NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE ACCOMPANYING PROXY STATEMENT.	Management	For	For

## FLEX PHARMA INC

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	33938A105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	FLKS	<b>Meeting Date</b>	07-Jun-2016
<b>Record Date</b>	11-Apr-2016		

<b>Item</b>	<b>Proposal</b>	<b>Proposed By</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1      MARC KOZIN		For	For
	2      RODERICK MACKINNON		For	For
	3      MICHELLE STACY		For	For
2.	TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

---

## FOAMIX PHARMACEUTICALS LTD

<b>Security</b>	M46135105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	FOMX	<b>Meeting Date</b>	18-Apr-2016
<b>Record Date</b>	15-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	APPOINT KESSELMAN & KESSELMAN, A MEMBER FIRM OF PRICEWATERHOUSECOOPERS INTERNATIONAL LIMITED, AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2016, AND AUTHORIZE THE BOARD TO DETERMINE THE COMPENSATION OF THE AUDITORS.	Management	For	For
2.	APPROVE THE FOLLOWING RESOLUTIONS WITH REGARD TO THE COMPENSATION OF DR. DOV TAMARKIN, OUR CHIEF EXECUTIVE OFFICER: (A) GRANT DR. TAMARKIN A CASH BONUS OF \$181,837 FOR THE YEAR ENDED DECEMBER 31, 2015, BASED ON THE ACHIEVEMENT OF THE GOALS SET AND EVALUATED BY OUR COMPENSATION COMMITTEE; (B) INCREASE DR. TAMARKIN'S ANNUAL BASE SALARY TO \$385,000, EFFECTIVE NOVEMBER 1, 2015; AND (C) AWARD DR. TAMARKIN 100,000 OPTIONS UNDER THE COMPANY'S 2015 ISRAELI SHARE INCENTIVE PLAN.	Management	For	For
2B.	IF YOU DO NOT HAVE A PERSONAL INTEREST MARK FOR= YES. IF YOU DO NOT MARK FOR=YES, YOUR VOTE FOR PROP 2 WILL NOT BE VALID	Management	For	
3.	APPROVE DR. TAMARKIN'S (A) ANNUAL CASH BONUS FOR THE YEAR ENDING DECEMBER 31, 2016, UP TO A MAXIMUM AMOUNT OF \$231,000, SUBJECT TO ACHIEVING THE KEY PERFORMANCE INDICATORS DETAILED IN THE PROXY STATEMENT, AND (B) AN ADDITIONAL SPECIAL CASH BONUS, FOR THE YEAR ENDING DECEMBER 31, 2016, IN AN AMOUNT OF UP TO \$231,000, UPON UNIQUE SUCCESS BEYOND EXPECTATIONS IN ACHIEVING CERTAIN GOALS DETAILED IN THE PROXY STATEMENT, IN EACH CASE, SUBJECT TO THE RECOMMENDATIONS OF THE COMPANY'S COMPENSATION COMMITTEE AND THE BOARD APPROVAL.	Management	Against	Against
3B.	IF YOU DO NOT HAVE A PERSONAL INTEREST MARK FOR= YES. IF YOU DO NOT MARK FOR=YES, YOUR VOTE FOR PROP 3 WILL NOT BE VALID	Management	For	
4.	APPROVE THE FOLLOWING RESOLUTIONS WITH REGARD TO THE COMPENSATION OF MEIR EINI, CHAIRMAN OF THE BOARD AND CHIEF INNOVATION OFFICER: (A) GRANT MR. EINI A	Management	Against	Against

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

CASH BONUS OF \$200,777 FOR THE YEAR ENDED DECEMBER 31, 2015, BASED ON THE ACHIEVEMENT OF THE GOALS SET AND EVALUATED BY OUR COMPENSATION COMMITTEE; (B) INCREASE MR. EINI S ANNUAL BASE SALARY TO \$369,000, EFFECTIVE NOVEMBER 1, 2015; AND (C) AWARD MR. EINI 55,000 OPTIONS UNDER THE COMPANY S 2015 ISRAELI SHARE INCENTIVE PLAN.

5.	APPROVE MR. EINI S (A) ANNUAL CASH BONUS FOR THE YEAR ENDING DECEMBER 31, 2016, UP TO A MAXIMUM AMOUNT OF \$184,500, SUBJECT TO ACHIEVING THE KEY PERFORMANCE INDICATORS DETAILED IN THIS PROXY STATEMENT, AND (B) AN ADDITIONAL SPECIAL CASH BONUS, FOR THE YEAR ENDING DECEMBER 31, 2016, IN AN AMOUNT OF UP TO \$184,500, UPON UNIQUE SUCCESS BEYOND EXPECTATIONS IN ACHIEVING CERTAIN GOALS DETAILED IN THIS PROXY STATEMENT, IN EACH CASE, SUBJECT TO THE RECOMMENDATIONS OF THE COMPANY S COMPENSATION COMMITTEE AND THE BOARD APPROVAL.	Management	Against	Against
----	--	------------	---------	---------

GALAPAGOS N V

<b>Security</b>	36315X101	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	GLPG	<b>Meeting Date</b>	22-Dec-2015
<b>Record Date</b>	8-Dec-2015		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	TO CONFIRM THE APPOINTMENT OF DR. CHRISTINE MUMMERY AS DIRECTOR OF THE COMPANY.	Management	For	For
2.	TO APPROVE THE PROPOSAL TO OFFER ADDITIONAL WARRANTS.	Management	For	For



## GALAPAGOS N V

<b>Security</b>	36315X101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GLPG	<b>Meeting Date</b>	26-Apr-2016
<b>Record Date</b>	7-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
2.	COMMUNICATION AND APPROVAL OF THE NON-CONSOLIDATED ANNUAL ACCOUNTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2015 AND THE ALLOCATION OF THE ANNUAL RESULT AS PROPOSED BY THE BOARD OF DIRECTORS.	Management	For	For
5.	COMMUNICATION AND APPROVAL OF THE REMUNERATION REPORT.	Management	For	For
6.	RELEASE FROM LIABILITY TO BE GRANTED TO THE DIRECTORS AND THE STATUTORY AUDITOR FOR THE PERFORMANCE OF THEIR DUTIES IN THE COURSE OF THE FINANCIAL YEAR ENDED 31 DECEMBER 2015.	Management	For	For
7.	REMUNERATION OF DIRECTORS.	Management	For	For
8.	OFFER OF WARRANTS.	Management	For	For
9.	APPLICATION OF ARTICLE 556 OF THE BELGIAN COMPANIES CODE.	Management	For	For
E2.	AUTHORIZATION TO THE BOARD OF DIRECTORS TO INCREASE THE SHARE CAPITAL WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL BY UP TO 20% OF THE SHARE CAPITAL.	Management	For	For
E3.	AUTHORIZATION TO THE BOARD OF DIRECTORS TO INCREASE THE SHARE CAPITAL WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL BY UP TO 50% OF THE SHARE CAPITAL, IN SPECIFIC CIRCUMSTANCES.	Management	For	For
E4.	AUTHORIZATION TO THE BOARD OF DIRECTORS TO INCREASE THE SHARE CAPITAL WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL BY UP TO 100% OF THE SHARE CAPITAL, IN SPECIFIC CIRCUMSTANCES WITH UNANIMOUS CONSENT.	Management	For	For
E5.	AUTHORIZATION TO THE BOARD OF DIRECTORS TO INCREASE THE SHARE CAPITAL WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL AFTER NOTIFICATION OF A PUBLIC TAKEOVER BID.	Management	For	For

## GALAPAGOS NV, MECHELEN

<b>Security</b>	B44170106	<b>Meeting Type</b>	Special General Meeting
<b>Ticker Symbol</b>	GLPG	<b>Meeting Date</b>	22-Dec-2015
<b>Record Date</b>	8-Dec-2015		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed By	Vote	For/Against Management
CMMT	IMPORTANT MARKET PROCESSING REQUIREMENT: A BENEFICIAL OWNER SIGNED POWER OF ATTORNEY (POA) MAY BE REQUIRED IN ORDER TO LODGE AND EXECUTE YOUR VOTING INSTRUCTIONS IN THIS MARKET. ABSENCE OF A POA, MAY CAUSE YOUR INSTRUCTIONS TO BE REJECTED. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT YOUR CLIENT SERVICE REPRESENTATIVE	Non-Voting		
CMMT	MARKET RULES REQUIRE DISCLOSURE OF BENEFICIAL OWNER INFORMATION FOR ALL VOTED ACCOUNTS. IF AN ACCOUNT HAS MULTIPLE BENEFICIAL OWNERS, YOU WILL NEED TO PROVIDE THE BREAKDOWN OF EACH BENEFICIAL OWNER NAME, ADDRESS AND SHARE-POSITION TO YOUR CLIENT SERVICE REPRESENTATIVE. THIS INFORMATION IS REQUIRED IN ORDER FOR YOUR VOTE TO BE LODGED	Non-Voting		
1	CONFIRMATION OF APPOINTMENT OF INDEPENDENT DIRECTOR: THE SHAREHOLDERS MEETING RESOLVES TO CONFIRM THE APPOINTMENT OF DR. CHRISTINE MUMMERY (RESIDING IN BILTHOVEN, THE NETHERLANDS) AS A DIRECTOR OF THE COMPANY, MADE BY THE BOARD AS FROM 30 SEPTEMBER 2015 TO FILL A VACANCY, AND TO APPOINT HER AS A DIRECTOR OF THE COMPANY FOR A PERIOD OF FOUR YEARS ENDING IMMEDIATELY AFTER THE SHAREHOLDERS MEETING IN 2019 WHICH HAS THE APPROVAL OF THE ANNUAL ACCOUNTS ON ITS AGENDA. UPON THE PROPOSAL OF THE BOARD AND IN ACCORDANCE WITH THE ADVICE OF THE COMPANY S NOMINATION AND REMUNERATION COMMITTEE, THE SHAREHOLDERS MEETING FURTHER RESOLVES TO APPOINT DR. MUMMERY AS AN INDEPENDENT DIRECTOR AS SHE MEETS THE CRITERIA OF INDEPENDENCE SET FORTH IN ARTICLE 526TER OF THE BELGIAN COMPANIES CODE AND DR. MUMMERY EXPRESSLY STATED, AND AS FAR AS THE BOARD IS AWARE, SHE DOES NOT HAVE ANY RELATIONSHIP WITH ANY COMPANY THAT WOULD COMPROMISE HER INDEPENDENCE. THE SHAREHOLDERS MEETING ACKNOWLEDGES THAT THE BOARD MAY DETERMINE THE REMUNERATION TO BE GRANTED TO DR. MUMMERY FOR THE EXERCISE OF HER MANDATE AS A DIRECTOR OF THE COMPANY WITHIN THE LIMITS OF THE POWER OF ATTORNEY UNANIMOUSLY APPROVED BY THE SHAREHOLDERS MEETING ON 28 APRIL 2015 (EIGHTH AGENDA ITEM - REMUNERATION OF DIRECTORS )	Management	For	For
2	OFFER OF WARRANTS: THE SHAREHOLDERS MEETING RESOLVES TO APPROVE THE PROPOSAL OF THE COMPANY S NOMINATION AND REMUNERATION COMMITTEE TO OFFER ADDITIONAL WARRANTS TO THE COMPANY S DIRECTORS IN LIGHT OF AN INDEPENDENT	Management	For	For

BENCHMARKING EXERCISE AND RECOMMENDATION BY AN EXTERNAL ADVISOR, FOLLOWING THE GROWTH OF THE COMPANY AND THE RECENT US LISTING OF THE COMPANY ON NASDAQ AND CONSEQUENTLY (I) RESOLVES TO OFFER 100,000 WARRANTS TO MR. ONNO VAN DE STOLPE, 15,000 WARRANTS TO DR. RAJ PAREKH, AND 7,500 WARRANTS TO EACH OF DR. WERNER CAUTREELS, DR. HARROLD VAN BARLINGEN, MR. HOWARD ROWE, MS. KATRINE BOSLEY AND DR. CHRISTINE MUMMERY, UNDER WARRANT PLANS TO BE CREATED BY THE BOARD OF DIRECTORS FOR THE BENEFIT OF DIRECTORS, EMPLOYEES AND INDEPENDENT CONSULTANTS OF GALAPAGOS AND ITS AFFILIATES WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL (JOINTLY WARRANT PLAN 2015 (B) ), THE KEY CONDITIONS OF WHICH WILL BE IN LINE WITH PREVIOUS WARRANT PLANS OF THE COMPANY, (II) EMPOWERS THE MANAGING DIRECTOR, AS WELL AS ANY OTHER DIRECTOR AS REGARDS THE OFFER TO THE MANAGING DIRECTOR, TO IMPLEMENT THIS OFFER, AND (III) TO THE EXTENT REQUIRED, APPROVES THE OFFER OF WARRANTS TO MEMBERS OF GALAPAGOS EXECUTIVE COMMITTEE UNDER WARRANT PLAN 2015 ... (DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL)

---

## GALAPAGOS NV, MECHELEN

<b>Security</b>	B44170106	<b>Meeting Type</b>	MIX
<b>Ticker Symbol</b>	GLPG	<b>Meeting Date</b>	26-Apr-2016
<b>Record Date</b>	12-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
CMMT	MARKET RULES REQUIRE DISCLOSURE OF BENEFICIAL OWNER INFORMATION FOR ALL VOTED ACCOUNTS. IF AN ACCOUNT HAS MULTIPLE BENEFICIAL OWNERS, YOU WILL NEED TO-PROVIDE THE BREAKDOWN OF EACH BENEFICIAL OWNER NAME, ADDRESS AND SHARE-POSITION TO YOUR CLIENT SERVICE REPRESENTATIVE. THIS INFORMATION IS REQUIRED IN ORDER FOR YOUR VOTE TO BE LODGED	Non-Voting		
CMMT	IMPORTANT MARKET PROCESSING REQUIREMENT: A BENEFICIAL OWNER SIGNED POWER OF ATTORNEY (POA) MAY BE REQUIRED IN ORDER TO LODGE AND EXECUTE YOUR VOTING INSTRUCTIONS IN THIS MARKET. ABSENCE OF A POA, MAY CAUSE YOUR INSTRUCTIONS TO BE REJECTED. IF YOU HAVE ANY QUESTIONS, PLEASE CONTACT YOUR CLIENT SERVICE REPRESENTATIVE	Non-Voting		
A.1	COMMUNICATION AND DISCUSSION OF THE ANNUAL REPORT OF THE BOARD OF DIRECTORS RELATING TO THE NON-CONSOLIDATED AND CONSOLIDATED ANNUAL ACCOUNTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2015, AND OF THE REPORT OF THE STATUTORY AUDITOR RELATING TO THE NON-CONSOLIDATED ANNUAL ACCOUNTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2015	Non-Voting		
A.2	THE SHAREHOLDERS MEETING RESOLVES TO APPROVE THE NON-CONSOLIDATED ANNUAL ACCOUNTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2015, AS WELL AS THE ALLOCATION OF THE ANNUAL RESULT AS PROPOSED BY THE BOARD OF DIRECTORS	Management	For	For
A.3	COMMUNICATION AND DISCUSSION OF THE REPORT OF THE STATUTORY AUDITOR RELATING TO THE CONSOLIDATED ANNUAL ACCOUNTS OF THE COMPANY FOR THE FINANCIAL YEAR-ENDED ON 31 DECEMBER 2015	Non-Voting		
A.4	COMMUNICATION AND DISCUSSION OF THE CONSOLIDATED ANNUAL ACCOUNTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDED ON 31 DECEMBER 2015	Non-Voting		
A.5	THE SHAREHOLDERS MEETING RESOLVES TO APPROVE THE REMUNERATION REPORT	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

A.6	THE SHAREHOLDERS MEETING RESOLVES, BY SEPARATE VOTE, TO RELEASE EACH DIRECTOR AND THE STATUTORY AUDITOR FROM ANY LIABILITY ARISING FROM THE PERFORMANCE OF THEIR DUTIES DURING THE LAST FINANCIAL YEAR	Management	For	For
A.7	UPON RECOMMENDATION OF THE COMPANY S NOMINATION AND REMUNERATION COMMITTEE, THE SHAREHOLDERS MEETING RESOLVES THAT (A) THE COMPENSATION (EXCLUDING EXPENSES) OF THE NON-EXECUTIVE DIRECTORS FOR THE EXERCISE OF THEIR MANDATE DURING THE FINANCIAL YEAR ENDING 31 DECEMBER 2016 IS ESTABLISHED AS FOLLOWS: (I) CHAIRMAN OF THE BOARD: EUR 80,000; (II) OTHER NON-EXECUTIVE BOARD MEMBERS: EUR 40,000 EACH; (III) ANNUAL ADDITIONAL COMPENSATION FOR MEMBERSHIP OF A BOARD COMMITTEE: EUR 5,000; (IV) ANNUAL ADDITIONAL COMPENSATION FOR THE CHAIRMANSHIP OF A BOARD COMMITTEE: EUR 10,000; AND (B) POWER OF ATTORNEY IS GRANTED TO THE BOARD OF DIRECTORS TO DETERMINE THE TOTAL REMUNERATION PACKAGE OF THE MANAGING DIRECTOR (CEO) FOR HIS MANAGEMENT FUNCTION IN THE COMPANY, IT BEING UNDERSTOOD THAT THIS REMUNERATION SHALL INCLUDE A COMPENSATION FOR THE PERFORMANCE OF HIS MANDATE AS A DIRECTOR OF THE COMPANY	Management	For	For
A.8	UPON RECOMMENDATION OF THE COMPANY S NOMINATION AND REMUNERATION COMMITTEE, THE SHAREHOLDERS MEETING (I) RESOLVES TO OFFER 100,000 WARRANTS TO MR. ONNO VAN DE STOLPE, 15,000 WARRANTS TO DR. RAJ PAREKH, AND 7,500 WARRANTS TO EACH OF DR. WERNER CAUTREELS, DR. HARROLD VAN BARLINGEN, MR. HOWARD ROWE, MS. KATRINE BOSLEY AND DR. CHRISTINE MUMMERY, UNDER WARRANT PLANS TO BE CREATED BY THE BOARD OF DIRECTORS FOR THE BENEFIT OF DIRECTORS, EMPLOYEES AND INDEPENDENT CONSULTANTS OF GALAPAGOS AND ITS AFFILIATES WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL (JOINTLY WARRANT PLAN 2016 ), THE KEY CONDITIONS OF WHICH WILL BE IN LINE WITH PREVIOUS WARRANT PLANS OF THE COMPANY, (II) EMPOWERS THE MANAGING DIRECTOR, AS WELL AS ANY OTHER DIRECTOR AS REGARDS THE OFFER TO THE MANAGING DIRECTOR, TO IMPLEMENT THIS OFFER, AND (III) TO THE EXTENT REQUIRED, APPROVES THE OFFER OF WARRANTS TO MEMBERS OF GALAPAGOS EXECUTIVE COMMITTEE UNDER WARRANT PLAN 2016 IN ACCORDANCE WITH GALAPAGOS REMUNERATION POLICY AND PRACTICES... (DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL)	Management	For	For
A.9	IN ACCORDANCE WITH ARTICLE 556 OF THE BELGIAN COMPANIES CODE, THE SHAREHOLDERS MEETING RESOLVES TO APPROVE, AND TO THE EXTENT REQUIRED,	Management	For	For

RATIFY ALL OF THE PROVISIONS GRANTING RIGHTS TO THIRD PARTIES WHICH COULD AFFECT THE ASSETS OF THE COMPANY, OR COULD IMPOSE AN OBLIGATION ON THE COMPANY, WHERE THE EXERCISE OF THOSE RIGHTS IS DEPENDENT ON A PUBLIC TAKEOVER BID ON THE SHARES OF THE COMPANY OR A CHANGE OF CONTROL IN RESPECT OF THE COMPANY, AS INCLUDED IN: (A) THE LICENSE AND COLLABORATION AGREEMENT BETWEEN GALAPAGOS NV AND GILEAD BIOPHARMACEUTICS IRELAND UNLIMITED COMPANY DATED 16 DECEMBER 2015 (THE LICENSE AND COLLABORATION AGREEMENT ) INCLUDING, BUT NOT LIMITED TO, CLAUSE 15.6 (ASSIGNMENT; INDUSTRY TRANSACTION; ACQUIRED PROGRAMS) OF THE LICENSE AND COLLABORATION AGREEMENT, ENTITLING THE COUNTERPARTY (I) IN THE EVENT OF AN INDUSTRY TRANSACTION INVOLVING THE COMPANY, AS A RESULT OF WHICH A DRUG COMPANY OF A CERTAIN MINIMUM SIZE ACQUIRES CONTROL OVER THE COMPANY, TO TERMINATE THE COMPANY S CO-PROMOTION RIGHTS, TO DISBAND ALL JOINT COMMITTEES AND UNDERTAKE EXCLUSIVE CONTROL OF THEIR ACTIVITIES; AND (II) IN THE EVENT OF A CHANGE OF CONTROL AS A RESULT OF WHICH THE COMPANY ACQUIRES RIGHTS TO AN ALTERNATIVE PRODUCT THAT WOULD VIOLATE CERTAIN OF COMPANY S EXCLUSIVITY OBLIGATIONS UNDER THE LICENSE AND COLLABORATION AGREEMENT...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL).

A.10	MISCELLANEOUS	Non-Voting		
E.1	CONSIDERATION AND DISCUSSION OF THE SPECIAL REPORT OF THE BOARD OF DIRECTORS- IN ACCORDANCE WITH ARTICLE 604 OF THE BELGIAN COMPANIES CODE RELATING TO THE RENEWAL OF ITS AUTHORIZATION WITH RESPECT TO, AND THE INCREASE OF, THE AUTHORIZED CAPITAL	Non-Voting		
E.2	THE SHAREHOLDERS MEETING RESOLVES TO DELETE SECTIONS (1) THROUGH (3) OF THE TEMPORARY PROVISIONS OF THE ARTICLES OF ASSOCIATION OF THE COMPANY ENTIRELY AND TO REPLACE THEM WITH THE FOLLOWING TEXT: AUTHORIZED CAPITAL THE BOARD OF DIRECTORS HAS BEEN GRANTED THE AUTHORITY TO INCREASE THE SHARE CAPITAL OF THE COMPANY, IN ACCORDANCE WITH ARTICLES 603 TO 608 OF THE COMPANIES CODE, IN ONE OR SEVERAL TIMES, TO THE EXTENT SET FORTH HEREAFTER. THIS AUTHORIZATION IS VALID FOR A PERIOD OF FIVE YEARS FROM THE DATE OF PUBLICATION OF THIS AUTHORIZATION IN THE ANNEXES TO THE BELGIAN STATE GAZETTE. WITHOUT PREJUDICE TO MORE RESTRICTIVE RULES SET FORTH BY LAW, THE BOARD OF DIRECTORS CAN INCREASE THE SHARE CAPITAL OF THE COMPANY IN ONE	Management	For	For

OR SEVERAL TIMES WITH AN AMOUNT OF UP TO EUR [AS SPECIFIED ], I.E. 20% OF THE SHARE CAPITAL AT THE TIME OF THE CONVENING OF THE SHAREHOLDERS MEETING GRANTING THIS AUTHORIZATION. IN ACCORDANCE WITH ARTICLE 607 OF THE COMPANIES CODE, THE BOARD OF DIRECTORS CANNOT USE THE AFOREMENTIONED AUTHORIZATION AFTER THE FINANCIAL SERVICES AND MARKETS AUTHORITY (FSMA) HAS NOTIFIED THE COMPANY OF A PUBLIC TAKEOVER BID FOR THE COMPANY S SHARES THE CAPITAL INCREASES WITHIN THE FRAMEWORK OF THE AUTHORIZED CAPITAL MAY BE ACHIEVED BY THE ISSUANCE OF SHARES (WITH OR WITHOUT VOTING RIGHTS...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL)

E.3	<p>SHAREHOLDERS MEETING RESOLVES TO ADD A NEW SECTION TO THE TEMPORARY PROVISIONS OF THE ARTICLES OF ASSOCIATION OF THE COMPANY, AS FOLLOWS: USE OF AUTHORIZED CAPITAL IN SPECIFIC CIRCUMSTANCES THE BOARD OF DIRECTORS HAS BEEN GRANTED THE AUTHORITY TO INCREASE THE SHARE CAPITAL OF THE COMPANY, IN ACCORDANCE WITH ARTICLES 603 TO 608 OF THE COMPANIES CODE, IN ONE OR SEVERAL TIMES, TO THE EXTENT SET FORTH HEREAFTER. THIS AUTHORIZATION IS VALID FOR A PERIOD OF FIVE YEARS FROM THE DATE OF PUBLICATION OF THIS AUTHORIZATION IN THE ANNEXES TO THE BELGIAN STATE GAZETTE. WITHOUT PREJUDICE TO MORE RESTRICTIVE RULES SET FORTH BY LAW, BUT ALSO WITHOUT PREJUDICE TO ANY OTHER LESS RESTRICTIVE AUTHORIZATIONS GRANTED BY THE EXTRAORDINARY SHAREHOLDERS MEETING OF [DATE OF THIS MEETING] 2016, THE BOARD OF DIRECTORS CAN INCREASE THE SHARE CAPITAL OF THE COMPANY IN ONE OR SEVERAL TIMES WITH AN AMOUNT UP TO EUR [ AS SPECIFIED], I.E. 50% OF THE SHARE CAPITAL AT THE TIME OF THE CONVENING OF THE SHAREHOLDERS MEETING GRANTING THIS AUTHORIZATION, UPON A RESOLUTION OF THE BOARD OF DIRECTORS THAT ALL INDEPENDENT DIRECTORS (WITHIN THE MEANING OF ARTICLE 526TER OF THE COMPANIES CODE) APPROVED AND RELATING TO ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL).</p>	Management	For	For
-----	--	------------	-----	-----

E.4	<p>THE SHAREHOLDERS MEETING RESOLVES TO ADD A NEW SECTION TO THE TEMPORARY PROVISIONS OF THE ARTICLES OF ASSOCIATION OF THE COMPANY, AS FOLLOWS: USE OF AUTHORIZED CAPITAL IN SPECIFIC CIRCUMSTANCES WITH UNANIMOUS CONSENT THE BOARD OF DIRECTORS HAS BEEN GRANTED THE AUTHORITY TO INCREASE THE SHARE CAPITAL OF THE COMPANY, IN ACCORDANCE WITH ARTICLES 603 TO 608 OF THE COMPANIES CODE, IN ONE OR SEVERAL TIMES, TO THE EXTENT SET FORTH HEREAFTER. THIS</p>	Management	For	For
-----	--	------------	-----	-----

AUTHORIZATION IS VALID FOR A PERIOD OF FIVE YEARS FROM THE DATE OF PUBLICATION OF THIS AUTHORIZATION IN THE ANNEXES TO THE BELGIAN STATE GAZETTE. WITHOUT PREJUDICE TO MORE RESTRICTIVE RULES SET FORTH BY LAW, BUT ALSO WITHOUT PREJUDICE TO ANY OTHER LESS RESTRICTIVE AUTHORIZATIONS GRANTED BY THE EXTRAORDINARY SHAREHOLDERS MEETING OF [DATE OF THIS MEETING] 2016, THE BOARD OF DIRECTORS CAN INCREASE THE SHARE CAPITAL OF THE COMPANY IN ONE OR SEVERAL TIMES WITH AN AMOUNT UP TO EUR [ AS SPECIFIED], I.E. 100% OF THE SHARE CAPITAL AT THE TIME OF THE CONVENING OF THE SHAREHOLDERS MEETING GRANTING THIS AUTHORIZATION...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL)

E.5	<p>THE SHAREHOLDERS MEETING RESOLVES TO ADD A NEW SECTION TO THE TEMPORARY PROVISIONS OF THE ARTICLES OF ASSOCIATION OF THE COMPANY, AS FOLLOWS: USE OF THE AUTHORIZATION TO INCREASE THE SHARE CAPITAL AFTER NOTIFICATION OF A PUBLIC TAKEOVER BID, UP TO ONE TENTH OF THE SHARES REPRESENTING THE CAPITAL OF THE COMPANY THAT IS ISSUED PRIOR TO SUCH CAPITAL INCREASE THE BOARD OF DIRECTORS IS EXPRESSLY AUTHORIZED DURING A PERIOD OF THREE YEARS AS OF THE DATE OF THE SHAREHOLDERS MEETING WHICH GRANTED THIS AUTHORIZATION, I.E. [DATE OF THIS MEETING] 2016, TO INCREASE THE COMPANY S SHARE CAPITAL WITHIN THE CONTEXT OF THE AUTHORIZED CAPITAL BY CONTRIBUTIONS IN KIND OR IN CASH WITH RESTRICTION OR CANCELLATION OF THE SHAREHOLDERS PREFERENTIAL SUBSCRIPTION RIGHTS, EVEN AFTER THE FINANCIAL SERVICES AND MARKETS AUTHORITY (FSMA) HAS NOTIFIED THE COMPANY OF A PUBLIC TAKEOVER BID FOR THE COMPANY S SHARES, PROVIDED THAT THE RELEVANT PROVISIONS OF THE COMPANIES CODE (INCLUDING BUT NOT LIMITED TO ARTICLE 607 OF THE COMPANIES CODE) ARE COMPLIED WITH, INCLUDING THAT THE NUMBER OF SHARES ISSUED UNDER SUCH CAPITAL INCREASE DOES NOT EXCEED ONE TENTH OF THE SHARES REPRESENTING THE CAPITAL OF THE COMPANY THAT HAVE BEEN ISSUED PRIOR TO SUCH CAPITAL INCREASE. USE OF THE AFOREMENTIONED AUTHORIZATION REQUIRES A UNANIMOUS RESOLUTION OF THE BOARD OF DIRECTORS AT WHICH ALL DIRECTORS ARE PRESENT OR REPRESENTED. THE AUTHORIZATION REFERRED TO ABOVE MAY BE RENEWED</p>	Management	For	For
-----	---	------------	-----	-----



## GENMARK DIAGNOSTICS, INC.

<b>Security</b>	372309104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GNMK	<b>Meeting Date</b>	26-May-2016
<b>Record Date</b>	30-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 LISA M. GILES		For	For
	2 MICHAEL S. KAGNOFF		For	For
2.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For
3.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS.	Management	For	For

## GILEAD SCIENCES, INC.

<b>Security</b>	375558103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	GILD	<b>Meeting Date</b>	11-May-2016
<b>Record Date</b>	16-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1A.	ELECTION OF DIRECTOR: JOHN F. COGAN, PH.D.	Management	For	For
1B.	ELECTION OF DIRECTOR: KEVIN E. LOFTON	Management	For	For
1C.	ELECTION OF DIRECTOR: JOHN W. MADIGAN	Management	For	For
1D.	ELECTION OF DIRECTOR: JOHN C. MARTIN, PH.D.	Management	For	For
1E.	ELECTION OF DIRECTOR: JOHN F. MILLIGAN, PH.D.	Management	For	For
1F.	ELECTION OF DIRECTOR: NICHOLAS G. MOORE	Management	For	For
1G.	ELECTION OF DIRECTOR: RICHARD J. WHITLEY, M.D.	Management	For	For
1H.	ELECTION OF DIRECTOR: GAYLE E. WILSON	Management	For	For
1I.	ELECTION OF DIRECTOR: PER WOLD-OLSEN	Management	For	For
2.	TO RATIFY THE SELECTION OF ERNST & YOUNG LLP BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF GILEAD FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For
3.	TO APPROVE THE AMENDED AND RESTATED GILEAD SCIENCES, INC. CODE SECTION 162(M) BONUS PLAN.	Management	For	For
4.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS PRESENTED IN THE PROXY STATEMENT.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

5.	TO VOTE ON A STOCKHOLDER PROPOSAL, IF PROPERLY PRESENTED AT THE MEETING, REQUESTING THAT THE BOARD TAKE STEPS TO PERMIT STOCKHOLDER ACTION BY WRITTEN CONSENT.	Shareholder	Against	For
----	--	-------------	---------	-----

---

**HALOZYME THERAPEUTICS, INC.**

<b>Security</b>	40637H109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	HALO	<b>Meeting Date</b>	04-May-2016
<b>Record Date</b>	10-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 JEFFREY W. HENDERSON		For	For
	2 CONNIE L. MATSUI		For	For
	3 HELEN I. TORLEY		For	For
2.	TO APPROVE, BY ADVISORY VOTE, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS.	Management	For	For
3.	TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For
4.	TO APPROVE AMENDMENTS TO THE COMPANY S 2011 STOCK PLAN.	Management	For	For
5.	TO APPROVE THE COMPANY S EXECUTIVE INCENTIVE PLAN.	Management	For	For

**IDEXX LABORATORIES, INC.**

<b>Security</b>	45168D104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	IDXX	<b>Meeting Date</b>	04-May-2016
<b>Record Date</b>	08-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.1	ELECTION OF DIRECTOR: JONATHAN W. AYERS	Management	For	For
1.2	ELECTION OF DIRECTOR: BARRY C. JOHNSON, PHD	Management	For	For
1.3	ELECTION OF DIRECTOR: M. ANNE SZOSTAK	Management	For	For
2.	TO RATIFY THE SELECTION OF PRICEWATERHOUSECOOPERS LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE CURRENT FISCAL YEAR	Management	For	For
3.	TO APPROVE A NONBINDING ADVISORY RESOLUTION ON THE COMPANY S EXECUTIVE COMPENSATION	Management	For	For

**ILLUMINA, INC.**

<b>Security</b>	452327109	<b>Meeting Type</b>	Annual
-----------------	-----------	---------------------	--------

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

**Ticker Symbol** ILMN **Meeting Date** 18-May-2016  
**Record Date** 21-Mar-2016

Item	Proposal	Proposed By	Vote	For/Against Management
1A.	ELECTION OF DIRECTOR: FRANCES ARNOLD, PH.D.	Management	For	For
1B.	ELECTION OF DIRECTOR: FRANCIS A. DESOUZA	Management	For	For
1C.	ELECTION OF DIRECTOR: KARIN EASTHAM, CPA	Management	For	For
2.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING JANUARY 1, 2017.	Management	For	For
3.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT.	Management	For	For
4.	TO APPROVE, ON AN ADVISORY BASIS, THE RATIFICATION OF CERTAIN SUPERMAJORITY VOTING PROVISIONS IN OUR CERTIFICATE OF INCORPORATION AND BYLAWS.	Management	For	For

**ILLUMINOSS MEDICAL, INC.**

**Security** N/A **Meeting Type** Written Consent  
**Ticker Symbol** N/A **Meeting Date** 05-Nov-2015  
**Record Date** N/A

Item	Proposal	Proposed by	Vote	For/Against Management
1	CONVERTIBLE NOTE FINANCING	Management	For	For
2	AMENDED CHARTER	Management	For	For
3	GENERAL RESOLUTIONS	Management	For	For

**ILLUMINOSS MEDICAL, INC.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	11-Jan-2016
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1	APPROVAL OF FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION	Management	For	For
2	SERIES AA PREFERRED STOCK PURCHASE AND EXCHANGE AGREEMENT	Management	For	For
3	WAIVER OF RIGHT OF SUBSCRIPTION RIGHTS	Management	For	For
4	AMENDMENT TO THE CORPORATION S 2007 STOCK OPTIONS/STOCK ISSUANCE PLAN	Management	For	For
5	BLUESKY AGREEMENT	Management	For	For
6	ELECTION OF DIRECTORS	Management	For	For
7	GENERAL RESOLUTIONS	Management	For	For

**IMPAX LABORATORIES, INC.**

<b>Security</b>	45256B101	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	IPXL	<b>Meeting Date</b>	08-Dec-2015
<b>Record Date</b>	26-Oct-2015		

<b>Item</b>	<b>Proposal</b>	<b>Proposed By</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	TO APPROVE AN AMENDMENT TO THE COMPANY S RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE AUTHORIZED NUMBER OF SHARES OF THE COMPANY S COMMON STOCK, PAR VALUE \$0.01 PER SHARE, FROM 90,000,000 SHARES TO 150,000,000 SHARES.	Management	For	For

**IMPAX LABORATORIES, INC.**

<b>Security</b>	45256B101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	IPXL	<b>Meeting Date</b>	17-May-2016
<b>Record Date</b>	06-Apr-2016		

<b>Item</b>	<b>Proposal</b>	<b>Proposed By</b>	<b>Vote</b>	<b>For/Against Management</b>
1.1	ELECTION OF DIRECTOR: LESLIE Z. BENET, PH.D.	Management	For	For
1.2	ELECTION OF DIRECTOR: ROBERT L. BURR	Management	For	For
1.3	ELECTION OF DIRECTOR: ALLEN CHAO, PH.D.	Management	For	For
1.4	ELECTION OF DIRECTOR: MARY K. PENDERGAST, J.D.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

1.5	ELECTION OF DIRECTOR: PETER R. TERRERI	Management	For	For
1.6	ELECTION OF DIRECTOR: JANET S. VERGIS	Management	For	For
1.7	ELECTION OF DIRECTOR: G. FREDERICK WILKINSON	Management	For	For
2.	TO APPROVE THE THIRD AMENDMENT AND RESTATEMENT OF OUR 2002 EQUITY INCENTIVE PLAN TO, AMONG OTHER ITEMS, INCREASE THE AGGREGATE NUMBER OF SHARES OF OUR COMMON STOCK THAT MAY BE ISSUED UNDER SUCH PLAN.	Management	For	For
3.	TO APPROVE, BY NON-BINDING VOTE, NAMED EXECUTIVE OFFICER COMPENSATION.	Management	For	For
4.	RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

**INCYTE CORPORATION**

<b>Security</b>	45337C102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	INCY	<b>Meeting Date</b>	27-May-2016
<b>Record Date</b>	08-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 JULIAN C. BAKER		For	For
	2 JEAN-JACQUES BIENAIME		For	For
	3 PAUL A. BROOKE		For	For
	4 PAUL J. CLANCY		For	For
	5 WENDY L. DIXON		For	For
	6 PAUL A. FRIEDMAN		For	For
	7 HERVE HOPPENOT		For	For
2.	TO APPROVE AMENDMENTS TO THE COMPANY S AMENDED AND RESTATED 2010 STOCK INCENTIVE PLAN.	Management	For	For
3.	TO APPROVE AN AMENDMENT TO THE COMPANY S 1997 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE THEREUNDER BY 500,000 SHARES, FROM 8,350,000 SHARES TO 8,850,000 SHARES.	Management	For	For
4.	TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS.	Management	For	For
5.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR 2016.	Management	For	For

## INOTEK PHARMACEUTICALS CORPORATION

<b>Security</b>	45780V102	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ITEK	<b>Meeting Date</b>	23-Jun-2016
<b>Record Date</b>	28-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	CARSTEN BOESS	For	For
	2	J. MARTIN CARROLL	For	For
	3	GARY M. PHILLIPS, M.D.	For	For
2.	RATIFICATION OF THE APPOINTMENT OF RSM US LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

## INSIGHTRA MEDICAL, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	13-Aug-2015
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	CONSENT TO AMENDMENTS TO CERTIFICATION OF DETERMINATION, ISSUANCE OF SECURITIES AND WAIVER OF ANTI-DILUTION	Management	For	For

## INSIGHTRA MEDICAL, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	29-Oct-2015
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	CONSENT OF ISSUANCE OF SECURITIES AND WAIVER OF FIRST OFFER	Management	For	For

## INSIGHTRA MEDICAL, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	24-Nov-2015
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	CONSENT TO NON-WHOLLY OWNED SUBSIDIARIES	Management	For	For

INSIGHTRA MEDICAL, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	19-Jan-2016
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	WAIVER OF FIRST OFFER AND WAIVER OF ANTI-DILUTION	Management	For	For

INSIGHTRA MEDICAL, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	12-Apr-2016
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	CONSENT AND WAIVER OF FIRST OFFER	Management	For	For

INSMED INCORPORATED

<b>Security</b>	457669307	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	INSM	<b>Meeting Date</b>	19-May-2016
<b>Record Date</b>	28-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 ALFRED F. ALTOMARI		For	For
	2 STEINAR J ENGELSEN M.D.		For	For
	3 WILLIAM H. LEWIS		For	For
2.	RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR INSMED INCORPORATED FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For





## INTRA-CELLULAR THERAPIES INC

<b>Security</b>	46116X101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ITCI	<b>Meeting Date</b>	14-Jun-2016
<b>Record Date</b>	20-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 SHARON MATES, PH.D.		For	For
	2 RORY B. RIGGS		For	For
	3 ROBERT L. VAN NOSTRAND		For	For
2.	PROPOSAL TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For
3.	TO APPROVE BY AN ADVISORY VOTE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.	Management	For	For
4.	TO APPROVE BY AN ADVISORY VOTE THE FREQUENCY OF HOLDING AN ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.	Management	1 Year	For

## JAZZ PHARMACEUTICALS PLC

<b>Security</b>	G50871105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	JAZZ	<b>Meeting Date</b>	30-Jul-2015
<b>Record Date</b>	01-Jun-2015		

Item	Proposal	Proposed By	Vote	For/Against Management
1A.	ELECTION OF DIRECTOR: PETER GRAY	Management	For	For
1B.	ELECTION OF DIRECTOR: KENNETH W. O'KEEFE	Management	For	For
1C.	ELECTION OF DIRECTOR: ELMAR SCHNEE	Management	For	For
1D.	ELECTION OF DIRECTOR: CATHERINE A. SOHN	Management	For	For
2.	TO APPROVE THE APPOINTMENT OF KPMG AS THE INDEPENDENT AUDITORS OF JAZZ PHARMACEUTICALS PLC FOR THE FISCAL YEAR ENDING DECEMBER 31, 2015 AND TO AUTHORIZE THE BOARD OF DIRECTORS, ACTING THROUGH THE AUDIT COMMITTEE, TO DETERMINE THE AUDITORS' REMUNERATION.	Management	For	For
3.	TO AUTHORIZE JAZZ PHARMACEUTICALS PLC AND/OR ANY SUBSIDIARY OF JAZZ PHARMACEUTICALS PLC TO MAKE MARKET PURCHASES OF JAZZ PHARMACEUTICALS PLC'S ORDINARY SHARES.	Management	For	For
4.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF JAZZ PHARMACEUTICALS PLC'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE PROXY STATEMENT.	Management	For	For

## MAGELLAN BIOSCIENCES, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	23-Mar-2016
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1	APPROVE SPECIFIED COMPENSATORY ARRANGEMENTS BETWEEN MAGELLAN BIOSCIENCES, INC. AND ITS NAMED EXECUTIVE OFFICERS RELATING TO THE TRANSACTION	Management	For	For

## MAGELLAN BIOSCIENCES, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	24-Mar-2016
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1	APPROVE THE RECEIPT OF MERGER CONSIDERATION BY VARIOUS INTERESTED ENTITIES AND INDIVIDUALS UNDER SECTION 144 OF THE DELAWARE GENERAL CORPORATION LAW	Management	For	For
2	APPROVAL OF MERGER AND RELATED TRANSACTIONS	Management	For	For
3	APPROVAL OF THE STOCKHOLDER REPRESENTATIVE	Management	For	For
4	WAIVER OF APPRAISAL RIGHTS	Management	For	For
5	ADDITIONAL AGREEMENTS AND ACKNOWLEDGEMENTS	Management	For	For
6	WAIVER OF NOTICE REQUIREMENTS	Management	For	For
7	OMNIBUS RESOLUTIONS	Management	For	For

---

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

**MEDIVATION, INC.**

<b>Security</b>	58501N101	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	MDVN	<b>Meeting Date</b>	22-Jun-2016
<b>Record Date</b>	25-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 KIM D. BLICKENSTAFF		For	For
	2 KATHRYN E. FALBERG		For	For
	3 DAVID T. HUNG, M.D.		For	For
	4 MICHAEL L. KING, PH.D.		For	For
	5 C. PATRICK MACHADO		For	For
	6 DAWN SVORONOS		For	For
	7 W. ANTHONY VERNON		For	For
	8 WENDY L. YARNO		For	For
2.	TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF PRICEWATERHOUSECOOPERS LLP AS MEDIVATION S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For
3.	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF MEDIVATION S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT OF MEDIVATION.	Management	For	For
4.	TO APPROVE AN AMENDMENT AND RESTATEMENT OF THE MEDIVATION, INC. AMENDED AND RESTATED 2004 EQUITY INCENTIVE AWARD PLAN TO INCREASE THE NUMBER OF SHARES OF MEDIVATION S COMMON STOCK RESERVED FOR ISSUANCE UNDER THE PLAN BY 1,600,000 SHARES AND MAKE CERTAIN OTHER CHANGES AS DESCRIBED IN PROPOSAL NO. 4 IN THE PROXY STATEMENT OF MEDIVATION.	Management	For	For
5.	THE SHAREHOLDER PROPOSAL REGARDING PROXY ACCESS, IF PROPERLY PRESENTED AT THE ANNUAL MEETING.	Shareholder	Against	For

**MERRIMACK PHARMACEUTICALS, INC.**

<b>Security</b>	590328100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	MACK	<b>Meeting Date</b>	14-Jun-2016
<b>Record Date</b>	19-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 ROBERT J. MULROY		For	For
	2 GARY L. CROCKER		For	For
	3 JOHN M. DINEEN		For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

	4	VIVIAN S. LEE, M.D. PHD		For	For
	5	JOHN MENDELSON, M.D.		For	For
	6	ULRIK B. NIELSEN, PH.D.		For	For
	7	MICHAEL E. PORTER, PH.D		For	For
	8	JAMES H. QUIGLEY		For	For
	9	RUSSELL T. RAY		For	For
2.		TO APPROVE, ON AN ADVISORY BASIS, OUR EXECUTIVE COMPENSATION.	Management	For	For
3.		TO RATIFY THE SELECTION OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

**MERUS B.V.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	24-Sep-2015
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	ADJUST THE EXERCISE PRICE OF THE OPTIONS UNDER THE OPTION PLAN 2010 AND REFUND ANY DIFFERENCES IN EXERCISE PRICE OF THE OPTIONS TO PARTICIPANTS	Management	For	For

**MERUS B.V.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	14-Oct-2015
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	GRANT OPTIONS UNDER THE MERUS B.V. 2010 OPTION PLAN AND SET THE EXERCISE PRICE FOR EACH OPTION	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

**MERUS B.V.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	22-Dec-2015
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	APPROVE PUBLICATION OF THE ANNUAL ACCOUNTS AND THE DIRECTOR S REPORT IN THE ENGLISH LANGUAGE	Management	For	For
2	ADOPT THE 2014 ANNUAL ACCOUNTS	Management	For	For
3	APPROVE TREATMENT OF LOSS CHARGED TO RESERVES	Management	For	For
4	APPROVE DISCHARGE OF MANAGEMENT BOARD FOR FISCAL 2014	Management	For	For
5	APPROVE DISCHARGE OF SUPERVISORY BOARD FOR FISCAL 2014	Management	For	For
6	APPROVE ANNUAL COMPENSATION TO CERTAIN NAMED INDEPENDENT DIRECTORS	Management	For	For
7	APPROVE GRANTS OF OPTIONS TO INDEPENDENT DIRECTORS	Management	For	For
8	APPROVE RENUMERATION OF AUDIT COMMITTEE CHAIRMAN	Management	For	For
9	APPROVE RENUMERATION OF COMPENSATION COMMITTEE CHAIRMAN	Management	For	For
10	RESOLVE THAT SUCH OPTIONS AND ANNUAL COMPENSATION IN CASH WHICH HAVE NOT YET BEEN GRANTED, SHALL LAPSE WITH IMMEDIATE EFFECT UPON THE EFFECTIVENESS OF THE 2015 PLAN.	Management	For	For

**MERUS B.V.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	08-Jan-2016
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	CONSENT TO SEND YOU THE CONVOCATION INCLUDING ALL NECESSARY INFORMATION FOR THE SHAREHOLDERS MEETINGS (GENERAL MEETING AND PREFERRED MEETING), WITHOUT TAKING INTO ACCOUNT THE CONVOCATION REQUIREMENTS, AS LONG AS THE MEETINGS ARE SCHEDULED IN 2016	Management	For	For
2	CONSENT TO DECIDING ON SUCH MATTERS BY WRITTEN RESOLUTION OUTSIDE A MEETING, AS AN ALTERNATIVE FOR OPTION 1, IF THE COMPANY DECIDES TO DO SO FOR PRACTICAL	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

REASONS

MERUS B.V.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	02-Mar-2016
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	RESOLUTION TO ISSUE OPTION SHARES UNDER THE MERUS B.V. 2010 EMPLOYEE OPTION PLAN	Management	For	For
2	RESOLUTION TO EXCLUDE PRE-EMPTIVE RIGHTS	Management	For	For

MERUS B.V.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	21-Mar-2016
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	GRANT INITIAL EQUITY AWARDS TO SELECT INDEPENDENT DIRECTORS AND ESTABLISH DATE OF GRANT, VESTING COMMENCEMENT DATE AND THE EXERCISE PRICE	Management	For	For

MERUS B.V.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	03-May-2016
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	ADOPT THE 2015 ACCOUNTS	Management	For	For
2	APPROVE TREATMENT OF LOSS CHARGED TO RESERVES	Management	For	For
3	APPROVE DISCHARGE OF MANAGEMENT BOARD FOR FISCAL 2015	Management	For	For
4	APPROVE DISCHARGE OF SUPERVISORY BOARD FOR FISCAL 2015	Management	For	For

**MERUS B.V.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	06-May-2016
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1	APPROVE THE AMENDMENT OF THE ARTICLES OF ASSOCIATION AND TO EFFECT A REVERSE STOCK SPLIT	Management	For	For
2	APPROVE THE CONVERSION OF THE COMPANY INTO A PUBLIC LIMITED LIABILITY COMPANY AND AMEND THE ARTICLES OF ASSOCIATION	Management	For	For
3	APPROVE ISSUANCE OF COMMON SHARES	Management	For	For
4	APPROVE THE CONVERSION OF ALL ISSUED PREFERRED SHARES INTO COMMON SHARES	Management	For	For
5	APPROVE RENUMERATION OF THE SUPERVISORY BOARD	Management	For	For
6A	APPROVE ANY REQUIRED APPLICATION TO NASDAQ	Management	For	For
6B	APPROVE OF THE COMPANY PERFORMING ALL ACTS AS THE MANAGEMENT BOARD DEEMS NECESSARY IN CONNECTION WITH OR CONDUCTIVE TO THE CONVERSION AND/OR IPO	Management	For	For
6C	APPROVE THE COMPANY RATIFYING AND CONFIRMING ANY DOCUMENT, DEED OR INSTRUMENT ALREADY EXECUTED IN RELATION TO THE CONVERSION AND/OR THE IPO	Management	For	For
6D	APPROVE THE TRANSFER OF THE SHARES TO SHAREHOLDERS OF CEDE & CO AFTER THE END OF THE LOCK-UP PERIOD BASED ON THE LOCK-UP AGREEMENT, IF APPLICABLE	Management	For	For
7	WAIVE ANY AND ALL PRE-EMPTIVE RIGHTS AND/OR ANTI-DILUTION PROTECTION IN RELATION TO ANY ISSUANCE OF COMMON SHARES AND/OR GRANTING RIGHTS TO SUBSCRIBE TO SHARES IN THE COMPANY S SHARE CAPITAL	Management	For	For
9	WAIVE ANY RIGHT OF FIRST REFUSAL THE PREFERRED SHAREHOLDERS MAY HAVE AND TO APPROVE SUCH TRANSFER	Management	For	For

**MERUS B.V.**

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	06-May-2016
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Vote</b>
-------------	-----------------	-------------



Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

		Proposed by		For/Against Management
1	APPROVE THE LISTING OF THE COMPANY S SHARES AT THE NASDAQ GLOBAL MARKET	Management	For	For
2	APPROVE A REVERSE STOCK SPLIT	Management	For	For
3	APPROVE THE CONVERSION OF THE COMPANY INTO A PUBLIC LIMITED LIABILITY COMPANY	Management	For	For
4	APPROVE THE ISSUANCE OF A NUMBER OF COMMON SHARES IN THE SHARE CAPITAL OF THE COMPANY TO THE PARTIES AND IN ACCORDANCE WITH THE NOTARIAL DEED OF ISSUE	Management	For	For
5	DELEGATE, TO THE MANAGEMENT BOARD, CERTAIN AUTHORITY TO ISSUE NEW SHARES AND GRANT RIGHTS	Management	For	For
6A	APPROVE RESTRICTION AND/OR EXCLUSION OF PRE-EMPTIVE RIGHTS	Management	For	For
6B	REPURCHASE SHARES IN THE CAPITAL OF THE COMPANY	Management	For	For
7A	THE RIGHT TO SUBSCRIBE FOR A NUMBER OF PREFERRED SHARES IN THE COMPANY S SHARE CAPITAL TO STICHTING CONTINUITEIT MERUS AND APPROVE THE ENTERING INTO A CALL OPTION AGREEMENT	Management	For	For
7B	APPROVE THAT THE MANAGEMENT BOARD SHALL PROVIDE A LOAN TO THE FOUNDATION FOR ITS PAYMENT OBLIGATIONS IN RELATION TO THE CALL OPTION	Management	For	For
8	DISMISS OR REAPPOINT CERTAIN MEMBERS OF THE SUPERVISORY BOARD	Management	For	For
9	ADOPT THE COMPANY S POLICY CONCERNING THE COMPENSATION OF THE MEMBERS OF THE MANAGEMENT BOARD	Management	For	For
10	ADOPT THE COMPANY S 2016 INCENTIVE AWARD PLAN	Management	For	For
11	APPROVE REMUNERATION OF SUPERVISORY BOARD	Management	For	For
12	APPROVE THE PROPOSAL OF THE MANAGEMENT BOARD TO DELETE CLAUSE 7.3 OF THE MERUS B.V. 2010 EMPLOYEE OPTION PLAN	Management	For	For
13.A	CANCEL 1,000 COMMON SHARES IN THE CAPITAL OF THE COMPANY HELD BY STICHTING ADMINISTRATIEKANTOOR MERUS	Management	For	For
13.B	CANCEL 225 COMMON SHARES IN THE CAPITAL OF THE COMPANY HELD BY STICHTING ADMINISTRATIEKANTOOR MERUS	Management	For	For
14	CONSENT TO SEND ALL INFORMATION TO THE SHAREHOLDERS BY ELECTRONIC MEANS	Management	For	For
15	DETERMINE THAT THE SHAREHOLDER S AGREEMENT SHALL TERMINATE AS PER THE EFFECTIVENESS OF THE REGISTRATION STATEMENT (WHETHER THE IPO QUALIFIES AS A QUALIFYING IPO AS DEFINED IN THE SHAREHOLDERS AGREEMENT OR NOT)	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

MYLAN N.V.

<b>Security</b>	N59465109	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	MYL	<b>Meeting Date</b>	28-Aug-2015
<b>Record Date</b>	31-Jul-2015		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	APPROVAL UNDER ARTICLE 2:107A OF THE DUTCH CIVIL CODE OF THE ACQUISITION, DIRECTLY OR INDIRECTLY (WHETHER BY WAY OF AN OFFER (AND SUBSEQUENT COMPULSORY ACQUISITION) OR ANY OTHER LEGAL ARRANGEMENT) OF ALL OR ANY PORTION OF THE ORDINARY SHARES OF PERRIGO COMPANY PLC ( PERRIGO ) OUTSTANDING (ON A FULLY DILUTED ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL).	Management	Against	Against

NATERA, INC.

<b>Security</b>	632307104	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NTRA	<b>Meeting Date</b>	07-Jun-2016
<b>Record Date</b>	19-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 JAMES I. HEALY		For	For
	2 EDWARD C. DRISCOLL, JR.		For	For
2.	PROPOSAL TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

NEUROCRINE BIOSCIENCES, INC.

<b>Security</b>	64125C109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	NBIX	<b>Meeting Date</b>	20-May-2016
<b>Record Date</b>	12-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 CORINNE H. NEVINNY		For	For
	2 RICHARD F. POPS		For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

3	STEPHEN SHERWIN, M.D.		For	For
2.	ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS.	Management	For	For
3.	TO APPROVE AN AMENDMENT TO THE COMPANY'S CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE FROM 110,000,000 TO 220,000,000.	Management	For	For
4.	TO APPROVE THE COMPANY'S 2011 EQUITY INCENTIVE PLAN, AS AMENDED.	Management	For	For
5.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

NEUROVANCE, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	11-Nov-2015
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	APPROVAL THAT THE TERMS AND CONDITIONS OF THE TERM SHEET, ARE JUST, EQUITABLE AND FAIR	Management	For	For
2	APPROVAL FOR THE COMPANY TO ENTER INTO A TERM SHEET WITH H.I.G. BIOVENTURES, LLC FOR A SERIES B PREFERRED STOCK FINANCING.	Management	For	For

## NEUROVANCE, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	09-Dec-2015
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1	INCREASE THE SIZE OF THE COMPANY'S BOARD TO SEVEN (7) MEMBERS	Management	For	For
2	APPROVE THE BOARD'S EXPANSION OF THE COMPANY'S BOARD OF DIRECTORS TO SEVEN (7) DIRECTORS; AND OF THE ELECTION OF MR. BAILEY TO FILL THE VACANCY CREATED BY THAT EXPANSION	Management	For	For
3	APPROVE OF THE BOARD'S HAVING AUTHORIZED AND DIRECTED THAT THE COMPANY SHOULD ENTER INTO A CONSULTING AGREEMENT; AS WELL AS AN ASSOCIATED, NONQUALIFIED STOCK OPTION FOR SHARES OF COMMON STOCK UNDER THE COMPANY'S 2011 EQUITY INCENTIVE PLAN	Management	For	For
4	AUTHORIZE, EMPOWER AND DIRECT THE CHIEF EXECUTIVE OFFICER TO TAKE ANY AND ALL ACTIONS SUCH OFFICER DEEMS NECESSARY OR APPROPRIATE TO IMPLEMENT THE FOREGOING RESOLUTIONS	Management	For	For

## NEUROVANCE, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	22-Feb-2016
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1	BRIDGE FINANCING	Management	For	For

## NEUROVANCE, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	29-Feb-2016
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
-------------	-----------------	--------------------	-------------	-------------------------------

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

1	SECOND CLOSING MAJORITY FOR BRIDGE FINANCING	Management	For	For
---	--	------------	-----	-----

NEUROVANCE, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	27-Jun-2016
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	BRIDGE FINANCING	Management	For	For

NEVRO CORP.

Security	64157F103	Meeting Type	Annual
Ticker Symbol	NVRO	Meeting Date	18-May-2016
Record Date	23-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 ALI BEHBAHANI, M.D.		For	For
	2 RAMI ELGHANDOUR		For	For
	3 WILFRED E. JAEGER, M.D.		For	For
2.	TO RATIFY THE SELECTION, BY THE AUDIT COMMITTEE OF THE COMPANY S BOARD OF DIRECTORS, OF PRICEWATERHOUSECOOPERS LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2016	Management	For	For
3.	TO RECOMMEND, ON A NON-BINDING, ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS	Management	1 Year	For

NOVAVAX, INC.

Security	670002104	Meeting Type	Annual
Ticker Symbol	NVAX	Meeting Date	09-Jun-2016
Record Date	13-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 GAIL K. BOUDREAUX		For	For
	2 MICHAEL A. MCMANUS, JR.		For	For
	3 JAMES F. YOUNG		For	For
2.		Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

TO AMEND AND RESTATE THE NOVAVAX, INC. 2015 STOCK INCENTIVE PLAN AND TO INCREASE THE NUMBER OF SHARES OF THE COMPANY S COMMON STOCK, PAR VALUE \$0.01, AVAILABLE FOR ISSUANCE THEREUNDER BY 6,000,000 SHARES.

3.	TO AMEND AND RESTATE THE NOVAVAX, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN AND TO INCREASE THE NUMBER OF SHARES OF THE COMPANY S COMMON STOCK, PAR VALUE \$0.01, AVAILABLE FOR ISSUANCE THEREUNDER BY 1,000,000 SHARES.	Management	For	For
4.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

---

## PARATEK PHARMACEUTICALS, INC.

<b>Security</b>	699374302	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	PRTK	<b>Meeting Date</b>	08-Jun-2016
<b>Record Date</b>	11-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 THOMAS J. DIETZ, PH.D.		For	For
	2 EVAN LOH, M.D.		For	For
	3 TIMOTHY R. FRANSON, M.D		For	For
2.	PROPOSAL WITHDRAWN	Management	Abstain	
3.	TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2016.	Management	For	For

## PIERIS PHARMACEUTICALS INC

<b>Security</b>	720795103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	PIRS	<b>Meeting Date</b>	28-Jun-2016
<b>Record Date</b>	06-May-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 CHAU KHUONG		For	For
	2 STEVEN PRELACK		For	For
2.	PROPOSAL TO APPROVE THE COMPANY S 2016 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN.	Management	For	For
3.	PROPOSAL TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY S INDEPENDENT PUBLIC ACCOUNTANTS FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

## REGENERON PHARMACEUTICALS, INC.

<b>Security</b>	75886F107	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	REGN	<b>Meeting Date</b>	10-Jun-2016
<b>Record Date</b>	14-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.1	ELECTION OF DIRECTOR: MICHAEL S. BROWN	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

1.2	ELECTION OF DIRECTOR: LEONARD S. SCHLEIFER	Management	For	For
1.3	ELECTION OF DIRECTOR: GEORGE D. YANCOPOULOS	Management	For	For
2.	RATIFICATION OF THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

RETROPHIN, INC.

<b>Security</b>	761299106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	RTRX	<b>Meeting Date</b>	18-May-2016
<b>Record Date</b>	23-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1	DIRECTOR	Management		
	1	STEPHEN ASELAGÉ	For	For
	2	TIM COUGHLIN	For	For
	3	CORNELIUS E. GOLDING	For	For
	4	JOHN KOZARICH	For	For
	5	GARY LYONS	For	For
	6	JEFFREY MECKLER	For	For
2	TO APPROVE THE COMPANY S 2015 EQUITY INCENTIVE PLAN, AS AMENDED, TO, AMONG OTHER ITEMS, INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE THEREUNDER BY 1,600,000.	Management	For	For
3	TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY S NAMED EXECUTIVE OFFICERS.	Management	For	For
4	TO RATIFY THE SELECTION OF BDO USA LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For



**REVANCE THERAPEUTICS, INC.**

<b>Security</b>	761330109	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	RVNC	<b>Meeting Date</b>	05-May-2016
<b>Record Date</b>	11-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 RONALD W. EASTMAN		For	For
	2 MARK A. PRYGOCKI		For	For
2.	PROPOSAL TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2016.	Management	For	For

**SAGE THERAPEUTICS, INC.**

<b>Security</b>	78667J108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	SAGE	<b>Meeting Date</b>	22-Jun-2016
<b>Record Date</b>	25-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1A.	ELECTION OF DIRECTOR: KEVIN P. STARR	Management	For	For
1B.	ELECTION OF DIRECTOR: JAMES FRATES	Management	For	For
2.	TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For
3.	ADVISORY VOTE ON THE FREQUENCY OF ADVISORY VOTES ON EXECUTIVE COMPENSATION.	Management	1 Year	For

**SHIRE PLC**

<b>Security</b>	82481R106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	SHPG	<b>Meeting Date</b>	28-Apr-2016
<b>Record Date</b>	18-Mar-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	TO RECEIVE THE COMPANY S ANNUAL REPORT AND ACCOUNTS FOR THE YEAR ENDED DECEMBER 31, 2015.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

2.	TO APPROVE THE DIRECTORS REMUNERATION REPORT, EXCLUDING THE DIRECTORS REMUNERATION POLICY, SET OUT ON PAGES 76 TO 101 OF THE ANNUAL REPORT AND ACCOUNTS FOR THE YEAR ENDED DECEMBER 31, 2015.	Management	For	For
3.	TO RE-ELECT DOMINIC BLAKEMORE AS A DIRECTOR.	Management	For	For
4.	TO ELECT OLIVIER BOHUON AS A DIRECTOR.	Management	For	For
5.	TO RE-ELECT WILLIAM BURNS AS A DIRECTOR.	Management	For	For
6.	TO RE-ELECT DR. STEVEN GILLIS AS A DIRECTOR.	Management	For	For
7.	TO RE-ELECT DR. DAVID GINSBURG AS A DIRECTOR.	Management	For	For
8.	TO RE-ELECT SUSAN KILSBY AS A DIRECTOR.	Management	For	For
9.	TO ELECT SARA MATHEW AS A DIRECTOR.	Management	For	For
10.	TO RE-ELECT ANNE MINTO AS A DIRECTOR.	Management	For	For
11.	TO RE-ELECT DR. FLEMMING ORNSKOV AS A DIRECTOR.	Management	For	For
12.	TO ELECT JEFFREY POULTON AS A DIRECTOR.	Management	For	For
13.	TO RE-APPOINT DELOITTE LLP AS THE COMPANY S AUDITOR UNTIL THE CONCLUSION OF THE NEXT ANNUAL GENERAL MEETING OF THE COMPANY.	Management	For	For
14.	TO AUTHORIZE THE AUDIT, COMPLIANCE & RISK COMMITTEE TO DETERMINE THE REMUNERATION OF THE AUDITOR.	Management	For	For
15.	THAT THE AUTHORITY TO ALLOT RELEVANT SECURITIES (AS DEFINED IN THE COMPANY S ARTICLES OF ASSOCIATION (THE ARTICLES )) CONFERRED ON THE DIRECTORS BY ARTICLE 10 PARAGRAPH (B) OF THE ARTICLES BE RENEWED AND FOR THIS PURPOSE THE AUTHORISED ALLOTMENT AMOUNT SHALL BE: (A) 9,886,710.20 OF RELEVANT SECURITIES; AND (B) SOLELY IN CONNECTION WITH AN ALLOTMENT PURSUANT TO AN OFFER BY WAY OF A RIGHTS ISSUE (AS DEFINED IN THE ARTICLES, BUT ONLY IF AND TO THE EXTENT THAT SUCH OFFER IS ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL)	Management	For	For
16.	THAT, SUBJECT TO THE PASSING OF RESOLUTION 15, THE AUTHORITY TO ALLOT EQUITY SECURITIES (AS DEFINED IN THE COMPANY S ARTICLES OF ASSOCIATION (THE ARTICLES )) WHOLLY FOR CASH CONFERRED ON THE DIRECTORS BY ARTICLE 10 PARAGRAPH (D) OF THE ARTICLES BE RENEWED AND FOR THIS PURPOSE THE NON PRE-EMPTIVE AMOUNT (AS DEFINED IN THE ARTICLES) SHALL BE 3,005,870.30 AND THE ALLOTMENT PERIOD SHALL BE THE PERIOD COMMENCING ON APRIL 28, 2016, AND ENDING ON THE EARLIER OF JULY 27, 2017, ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL)	Management	For	For
17.	THAT THE COMPANY BE AND IS HEREBY GENERALLY AND UNCONDITIONALLY AUTHORIZED: (A) PURSUANT TO ARTICLE 57 OF THE COMPANIES (JERSEY) LAW 1991 TO MAKE MARKET PURCHASES OF ORDINARY SHARES IN THE CAPITAL OF THE COMPANY, PROVIDED THAT: (1) THE MAXIMUM NUMBER OF ORDINARY SHARES HEREBY AUTHORIZED TO BE PURCHASED IS 59,320,261; (2) THE MINIMUM	Management	For	For

	PRICE, EXCLUSIVE OF ANY EXPENSES, WHICH MAY BE PAID FOR AN ORDINARY SHARE IS FIVE PENCE; (3) THE MAXIMUM PRICE, EXCLUSIVE OF ANY EXPENSES, WHICH MAY BE PAID ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL)			
18.	THAT THE AUTHORIZED SHARE CAPITAL OF THE COMPANY BE INCREASED FROM 50,000,002 TO 75,000,002, TO BE DIVIDED INTO 1,500,000,000 SHARES DESIGNATED AS ORDINARY SHARES WITH A PAR VALUE OF 5P EACH AND 2 SHARES DESIGNATED AS SUBSCRIBER ORDINARY SHARES WITH A PAR VALUE OF 1 EACH, AND THAT THE COMPANY S MEMORANDUM OF ASSOCIATION BE AMENDED ACCORDINGLY.	Management	For	For
19.	THAT, WITH EFFECT FROM THE CONCLUSION OF THE ANNUAL GENERAL MEETING, THE COMPANY S ARTICLES OF ASSOCIATION BE AMENDED AND THOSE ARTICLES PRODUCED TO THE MEETING AND INITIALED BY THE CHAIRMAN BE ADOPTED AS THE COMPANY S ARTICLES OF ASSOCIATION, IN SUBSTITUTION FOR, AND TO THE EXCLUSION OF, THE EXISTING ARTICLES OF ASSOCIATION OF THE COMPANY.	Management	For	For
20.	TO APPROVE THAT A GENERAL MEETING OF THE COMPANY, OTHER THAN AN ANNUAL GENERAL MEETING, MAY BE CALLED ON NOT LESS THAN 14 CLEAR DAYS NOTICE.	Management	For	For

## SHIRE PLC

<b>Security</b>	82481R106	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	SHPG	<b>Meeting Date</b>	27-May-2016
<b>Record Date</b>	21-Apr-2016		

<b>Item</b>	<b>Proposal</b>	<b>Proposed By</b>	<b>Vote</b>	<b>For/Against Management</b>
1	APPROVAL OF THE MERGER, ALLOTMENT OF SHARES AND INCREASE IN BORROWING LIMIT THAT: (A) THE PROPOSED COMBINATION BY THE COMPANY, THROUGH ITS WHOLLY-OWNED SUBSIDIARY, BEARTRACKS, INC., WITH THE OUTSTANDING COMMON STOCK WITH BAXALTA INC. (THE MERGER ), ON THE TERMS AND CONDITIONS SET OUT IN THE MERGER AGREEMENT (AS DEFINED IN, AND PARTICULARS OF WHICH ARE SUMMARISED IN, THE CIRCULAR OF THE COMPANY DATED 18 APRIL 2016), TOGETHER WITH ALL OTHER AGREEMENTS AND ANCILLARY ARRANGEMENTS ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL)	Management	For	For
2	AUTHORITY TO ALLOT SHARES THAT, SUBJECT TO AND CONDITIONAL UPON THE MERGER HAVING BEEN IMPLEMENTED AND THE NEW ORDINARY SHARES IN THE COMPANY HAVING BEEN ISSUED PURSUANT THERETO, ANY PREVIOUS AUTHORITY TO ALLOT RELEVANT SECURITIES (AS DEFINED IN THE ARTICLES), CONFERRED ON THE DIRECTORS BY SHAREHOLDERS PURSUANT TO ARTICLE 10 OF THE ARTICLES (INCLUDING ANY UNUSED AUTHORITY CONFERRED BY RESOLUTION 1 ABOVE) BE CANCELLED AND THE AUTHORITY TO ALLOT RELEVANT SECURITIES CONFERRED ON THE ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL)	Management	For	For
3	DISAPPLICATION OF PRE-EMPTION RIGHTS: THAT, SUBJECT TO THE PASSING OF RESOLUTION 2 AND SUBJECT TO AND CONDITIONAL UPON THE MERGER HAVING BEEN IMPLEMENTED AND THE NEW ORDINARY SHARES IN THE COMPANY HAVING BEEN ISSUED PURSUANT THERETO, ANY PREVIOUS AUTHORITY TO ALLOT EQUITY SECURITIES (AS DEFINED IN THE ARTICLES) WHOLLY FOR CASH CONFERRED ON THE DIRECTORS BY SHAREHOLDERS PURSUANT TO ARTICLE 10 OF THE ARTICLES OF ASSOCIATION BE CANCELLED AND THE AUTHORITY TO ALLOT EQUITY ... (DUE TO SPACE LIMITS, SEE PROXY MATERIAL FOR FULL PROPOSAL)	Management	For	For
4	PURCHASE OF OWN SHARES: THAT, SUBJECT TO AND CONDITIONAL UPON THE MERGER HAVING BEEN IMPLEMENTED AND THE NEW ORDINARY	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

SHARES IN THE COMPANY HAVING BEEN ISSUED  
PURSUANT THERETO, ANY PREVIOUS  
AUTHORITY CONFERRED ON THE COMPANY TO  
MAKE MARKET PURCHASES OF ITS SHARES AND  
TO HOLD TREASURY SHARES BE CANCELLED  
AND THE COMPANY BE GENERALLY AND  
UNCONDITIONALLY AUTHORISED: (A) PURSUANT  
TO ARTICLE 57 OF THE COMPANIES (JERSEY) LAW  
1991 TO MAKE MARKET PURCHASES OF  
ORDINARY SHARES IN THE ... (DUE TO SPACE  
LIMITS, SEE PROXY MATERIAL FOR FULL  
PROPOSAL)

---

**TETRAPHASE PHARMACEUTICALS, INC.**

<b>Security</b>	88165N105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	TTPH	<b>Meeting Date</b>	08-Jun-2016
<b>Record Date</b>	14-Apr-2016		

<b>Item</b>	<b>Proposal</b>	<b>Proposed By</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	DIRECTOR	Management		
	1 GAREN BOHLIN		For	For
	2 JOHN FREUND		For	For
2.	TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016	Management	For	For
3.	TO APPROVE, ON AN ADVISORY BASIS, OUR EXECUTIVE COMPENSATION	Management	For	For
4.	TO RECOMMEND, ON AN ADVISORY BASIS, THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION	Management	1 Year	For

**TEVA PHARMACEUTICAL INDUSTRIES LIMITED**

<b>Security</b>	881624209	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	TEVA	<b>Meeting Date</b>	03-Sep-2015
<b>Record Date</b>	04-Aug-2015		

<b>Item</b>	<b>Proposal</b>	<b>Proposed By</b>	<b>Vote</b>	<b>For/Against Management</b>
1A	ELECTION OF DIRECTOR: ROGER ABRAVANEL	Management	For	For
1B	ELECTION OF DIRECTOR: ROSEMARY A. CRANE	Management	For	For
1C	ELECTION OF DIRECTOR: GERALD M. LIEBERMAN	Management	For	For
1D	ELECTION OF DIRECTOR: GALIA MAOR	Management	For	For
2	TO APPOINT GABRIELLE GREENE-SULZBERGER TO SERVE AS A STATUTORY INDEPENDENT DIRECTOR FOR A TERM OF THREE YEARS, COMMENCING FOLLOWING THE MEETING, AND TO APPROVE HER REMUNERATION AND BENEFITS.	Management	For	For
3A	TO APPROVE AN AMENDMENT TO THE COMPANY S COMPENSATION POLICY WITH RESPECT TO DIRECTOR REMUNERATION.	Management	For	For
3A1	DO YOU HAVE A PERSONAL INTEREST IN PROPOSAL 3A? NOTE: PROPOSAL 3A1, FOR=YES AGAINST=NO	Management	Against	
3B	TO APPROVE THE REMUNERATION TO BE PROVIDED TO THE COMPANY S DIRECTORS.	Management	For	For
3C	TO APPROVE THE REMUNERATION TO BE PROVIDED TO PROF. YITZHAK PETERBURG, CHAIRMAN OF THE BOARD OF DIRECTORS.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

4A	TO APPROVE AN AMENDMENT TO THE TERMS OF OFFICE AND EMPLOYMENT OF THE COMPANY'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, MR. EREZ VIGODMAN.	Management	For	For
4B	TO APPROVE THE PAYMENT OF A SPECIAL BONUS TO THE COMPANY'S PRESIDENT AND CHIEF EXECUTIVE OFFICER, MR. EREZ VIGODMAN.	Management	For	For
5	TO APPROVE THE COMPANY'S 2015 LONG-TERM EQUITY-BASED INCENTIVE PLAN.	Management	For	For
6	TO APPOINT KESSELMAN & KESSELMAN, A MEMBER OF PRICEWATERHOUSECOOPERS INTERNATIONAL LTD., AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM UNTIL THE 2016 ANNUAL MEETING OF SHAREHOLDERS.	Management	For	For

---

**TEVA PHARMACEUTICAL INDUSTRIES LIMITED**

<b>Security</b>	881624209	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	TEVA	<b>Meeting Date</b>	05-Nov-2015
<b>Record Date</b>	06-Oct-2015		

<b>Item</b>	<b>Proposal</b>	<b>Proposed By</b>	<b>Vote</b>	<b>For/Against Management</b>
1	APPROVAL OF THE CREATION OF A NEW CLASS OF MANDATORY CONVERTIBLE PREFERRED SHARES, NOMINAL (PAR) VALUE NIS 0.1 PER SHARE AND THE DEFINITION OF THEIR TERMS, AND CERTAIN RELATED AMENDMENTS TO TEVA S ARTICLES OF ASSOCIATION AND MEMORANDUM OF ASSOCIATION.	Management	For	For

**THE MEDICINES COMPANY**

<b>Security</b>	584688105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	MDCO	<b>Meeting Date</b>	26-May-2016
<b>Record Date</b>	15-Apr-2016		

<b>Item</b>	<b>Proposal</b>	<b>Proposed By</b>	<b>Vote</b>	<b>For/Against Management</b>
1A.	ELECTION OF DIRECTOR: WILLIAM W. CROUSE	Management	For	For
1B.	ELECTION OF DIRECTOR: JOHN C. KELLY	Management	For	For
1C.	ELECTION OF DIRECTOR: HIROAKI SHIGETA	Management	For	For
2.	APPROVE AN AMENDMENT TO THE COMPANY S CERTIFICATE OF INCORPORATION TO PROVIDE FOR THE PHASED DECLASSIFICATION OF OUR BOARD OF DIRECTORS TO BE COMPLETED UPON THE ELECTION OF DIRECTORS AT OUR 2018 ANNUAL MEETING OF STOCKHOLDERS.	Management	For	For
3.	APPROVE THE 2013 STOCK INCENTIVE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF AUTHORIZED SHARES.	Management	For	For
4.	APPROVE THE 2010 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF AUTHORIZED SHARES.	Management	For	For
5.	APPROVE, IN AN ADVISORY VOTE, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS PRESENTED IN THE PROXY STATEMENT.	Management	For	For
6.	RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2016.	Management	For	For

**THEROX, INC.**



Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	20-Apr-2016
<b>Record Date</b>	N/A		

<b>Item</b>	<b>Proposal</b>	<b>Proposed by</b>	<b>Vote</b>	<b>For/Against Management</b>
1	APPROVAL OF REVERSE STOCK SPLIT	Management	For	For

**TROVAGENE, INC**

<b>Security</b>	897238309	<b>Meeting Type</b>	Special
<b>Ticker Symbol</b>	TROV	<b>Meeting Date</b>	23-Dec-2015
<b>Record Date</b>	12-Oct-2015		

<b>Item</b>	<b>Proposal</b>	<b>Proposed By</b>	<b>Vote</b>	<b>For/Against Management</b>
1.	PROPOSAL TO ADOPT AN AMENDMENT TO THE TROVAGENE INC. 2014 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES RESERVED FOR ISSUANCE THEREUNDER TO 7,500,000 FROM 5,000,000.	Management	For	For

**ULTRAGENYX PHARMACEUTICAL INC.**

<b>Security</b>	90400D108	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	RARE	<b>Meeting Date</b>	09-Jun-2016
<b>Record Date</b>	12-Apr-2016		

<b>Item</b>	<b>Proposal</b>	<b>Proposed By</b>	<b>Vote</b>	<b>For/Against Management</b>
1A.	ELECTION OF DIRECTOR: WILLIAM ALISKI	Management	For	For
1B.	ELECTION OF DIRECTOR: LARS EKMAN, M.D., PH.D.	Management	For	For
1C.	ELECTION OF DIRECTOR: MATTHEW K. FUST	Management	For	For
2.	RATIFICATION OF THE SELECTION OF ERNST & YOUNG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For
3.	ADVISORY (NON-BINDING) VOTE TO APPROVE THE COMPANY S EXECUTIVE COMPENSATION.	Management	For	For
4.	ADVISORY (NON-BINDING) VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE EXECUTIVE COMPENSATION.	Management	1 Year	For

## VENITI, INC.

<b>Security</b>	N/A	<b>Meeting Type</b>	Written Consent
<b>Ticker Symbol</b>	N/A	<b>Meeting Date</b>	04-Dec-2015
<b>Record Date</b>	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	INCREASE IN SIZE OF BOARD; AMENDMENT OF VOTING AGREEMENT	Management	For	For
2	INCREASE IN 2010 EQUITY INCENTIVE PLAN	Management	For	For
3	OMNIBUS RESOLUTIONS	Management	For	For

## VERTEX PHARMACEUTICALS INCORPORATED

<b>Security</b>	92532F100	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	VRTX	<b>Meeting Date</b>	15-Jun-2016
<b>Record Date</b>	20-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 JOSHUA BOGER		For	For
	2 TERRENCE C. KEARNEY		For	For
	3 YUCHUN LEE		For	For
	4 ELAINE S. ULLIAN		For	For
2.	RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2016.	Management	For	For
3.	ADVISORY VOTE ON OUR NAMED EXECUTIVE OFFICER COMPENSATION.	Management	For	For
4.	SHAREHOLDER PROPOSAL, IF PROPERLY PRESENTED AT THE MEETING, REQUESTING THAT WE TAKE NECESSARY STEPS TO DECLASSIFY OUR BOARD OF DIRECTORS.	Shareholder	Against	For
5.	SHAREHOLDER PROPOSAL, IF PROPERLY PRESENTED AT THE MEETING, REQUESTING THAT WE ADOPT A POLICY LIMITING ACCELERATION OF EQUITY AWARDS TO SENIOR EXECUTIVES UPON A CHANGE OF CONTROL.	Shareholder	Against	For
6.	SHAREHOLDER PROPOSAL, IF PROPERLY PRESENTED AT THE MEETING, REQUESTING THAT WE ADOPT A POLICY REQUIRING THAT SENIOR EXECUTIVES RETAIN A PERCENTAGE OF THEIR EQUITY AWARDS.	Shareholder	Against	For
7.	SHAREHOLDER PROPOSAL, IF PROPERLY PRESENTED AT THE MEETING, REQUESTING A REPORT ASSESSING THE FEASIBILITY OF INTEGRATING SUSTAINABILITY INTO PERFORMANCE MEASURES FOR SENIOR EXECUTIVE COMPENSATION.	Shareholder	Against	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

**XENCOR INC**

<b>Security</b>	98401F105	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	XNCR	<b>Meeting Date</b>	23-Jun-2016
<b>Record Date</b>	26-Apr-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 DR. BRUCE L.A. CARTER		For	For
	2 ROBERT BALTERA, JR		For	For
	3 DR. BASSIL I. DAHIYAT		For	For
	4 KURT GUSTAFSON		For	For
	5 YUJIRO S. HATA		For	For
	6 DR. A. BRUCE MONTGOMERY		For	For
2.	PROPOSAL TO RATIFY RSM US, LLP AS THE INDEPENDENT PUBLIC ACCOUNTING FIRM FOR 2016.	Management	For	For

**ZAFGEN, INC.**

<b>Security</b>	98885E103	<b>Meeting Type</b>	Annual
<b>Ticker Symbol</b>	ZFGN	<b>Meeting Date</b>	30-Jun-2016
<b>Record Date</b>	02-May-2016		

Item	Proposal	Proposed By	Vote	For/Against Management
1.1	ELECTION OF DIRECTOR: PETER BARRETT, PH.D.	Management	For	For
1.2	ELECTION OF DIRECTOR: FRANCES K. HELLER	Management	For	For
1.3	ELECTION OF DIRECTOR: BRUCE BOOTH, PH.D.	Management	For	For
2.	TO RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2016.	Management	For	For

**SIGNATURES**

Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant)                      Tekla Life Sciences Investors

By (Signature and Title)\*

/s/ Daniel R. Omstead  
(Daniel R. Omstead, President)

Date    8/29/16

---

\*Print the name and title of each signing officer under his or her signature.